University at Buffalo - The State University of New York
Skip to Content
Sanjay                         Sethi

Sanjay Sethi MD

Department of Medicine

Professor and Chief, Pulmonary, Critical Care and Sleep Medicine; Assistant Vice President for Health Sciences

Specialty/Research Focus

Pulmonary & Critical Care Medicine

 
Professional Summary:

As chief of the division of pulmonary, critical care and sleep medicine, I oversee clinical, teaching, research and administrative tasks related to the evaluation and treatment of adult patients with lung diseases and sleep disorders as well as critically ill patients. My practice is primarily located at the VA Medical Center (VA) in Buffalo; however, members of my division provide care at sites throughout Buffalo, including the UBMD clinic at UBMD Internal Medicine at Amherst, UBMD Sleep Center and other UB-affiliated hospitals.

I also conduct research on one of the most common lung diseases: chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, and lung infections such as bronchitis and pneumonia. Interestingly, patients with COPD become more prone to lung infection, and understanding why and how this happens is my main research interest. In addition to bench research in this field, I am also working to develop better ways to prevent and treat these infections by leading and participating in several clinical research studies in this field that are open to both veterans and the general public. I lead a multidisciplinary research team based at the VA that includes pulmonary and infectious disease physicians, post-doctoral scientists, nurse coordinators and research assistants. Through mentored research programs, our laboratories train undergraduate and graduate students, residents and fellows.

I am active in several professional organizations and have served as a consultant on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

Education and Training:
  • Fellowship, Pulmonary and Critical Care, University at Buffalo (1993)
  • Residency, Cook County Hospital (1990)
  • Internship, Cook County Hospital (1988)
  • MBBS, Maulana Azad Medical College (1984)
Employment:
  • Vice Chair for Research, Department of Medicine, University at Buffalo (2011-present)
  • Staff Physician, Division of Pulmonary, Critical Care and Sleep Medicine, VA Western New York Healthcare System (2010-present)
  • Chief, Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo (2007-present)
  • Professor, Medicine, University at Buffalo (2006-present)
  • Section Chief, Division of Pulmonary, Critical Care and Sleep Medicine, VA Western NY Healthcare System (2007–2010)
  • Staff Physician, Division of Pulmonary, Critical Care and Sleep Medicine, VA Western New York Healthcare System (1993–2007)
  • Associate Professor, Medicine, University at Buffalo (2001–2006)
  • Assistant Professor, Medicine, University at Buffalo (1996–2001)
  • Research Assistant Professor, Medicine, University at Buffalo (1993–1996)
  • Buswell Research Fellow, Medicine, University at Buffalo (1993–1996)
  • Fellow, University at Buffalo (1990–1993)
  • Clinical Instructor, Modern Languages & Literature, University at Buffalo (1990–1993)
See all (2 more)
Awards and Honors:
  • Expertscape Recognition (2013)
  • Fellow of the American College of Physicians
  • Who‘s Who in Science and Engineering
  • Merit Scholarships awarded by Delhi University based on performance in the
  • Honorable mention for performance as intern and resident at Cook County Hospital
  • Distinguished Scientist and Sustained Achievement Award, University at Buffalo

Research Expertise:
  • Bacterial infection in COPD
  • Epidemiology and clinical implications of antimicrobial resistance
  • Innate lung defense in COPD
  • New therapeutics in COPD
UB 2020 Strategic Strengths:
  • Health and Wellness Across the Lifespan
Grants and Sponsored Research:
  • January 2016–January 2020
    Clinical Translational Science Award (CTSA)
    National Institutes of Health
    Role: Co-Investigator
    $16,000,000
  • September 2012–September 2014
    A Randomized, Double-blind, Placebo-controlled Study to evaluate the safety of long term use of Perforomist (formoterol fumarate) inhalation solution in subjects with COPD. Direct costs - $6,000/subject.
    Dey
    Role: Principal Investigator
  • September 2010–August 2014
    Bacterial Infection in COPD
    VA Merit Review
    Role: Principal Investigator
    $550,000
  • August 2012–July 2014
    A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 (IL1RA) in Chronic Obstructive Pulmonary Disease. Direct costs -$27,000/subject.
    Medimmune
    Role: Principal Investigator
    $27,000
  • September 2010–August 2013
    Enhancing Nrf2 by Sulforaphane Treatment in COPD as a Novel Interventional Strategy
    National Heart, Lung and Blood Institute
    Role: Principal Investigator
    $360,000
  • September 2010–August 2013
    Sulforaphane Treatment in COPD as a Novel Interventional Strategy to Enhance Innate Immunity
    National Heart, Lung and Blood Institute
    Role: Principal Investigator
    $350,000
  • July 2010–June 2013
    Investigating the presence and role of biofilms in COPD and their potential contribution to exacerbations of COPD.
    Astra Zeneca
    Role: Principal Investigator
    $400,000
  • April 2011–April 2013
    Defining the Mechanisms of the Increased Risk of Community Acquired Pneumonia in COPD Patients Treated with Inhaled Corticosteroids
    Astra Zeneca
    Role: Co-Investigator
    $218,880
  • December 2010–December 2012
    Defining a Role for Inhaled Calcium in Augmenting the Alveolar Macrophage Innate Immune Response to Infection in COPD
    Pulmatrix
    Role: Co-Investigator
    $115,200
  • July 2009–June 2012
    A six month Randomized Controlled Trial of Lung Flute in Patients with COPD
    Medical Acoustics, Inc
    Role: Principal Investigator
    $210,000
  • June 2010–September 2010
    Determination of in vitro effects of iCALM on COPD sputum.
    Pulmatrix
    Role: Principal Investigator
    $35,000
  • March 2005–August 2010
    Bacterial infection in COPD.
    VA Merit Review
    Role: Principal Investigator
  • July 2010–June 2010
    A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID in Comparison to Salmeterol 50mcg BID on the Rate of Exacerbations of COPD Following Hospitalization.
    Glaxo Smith Kline
    Role: Co-Investigator
  • December 2008–April 2010
    Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to prevent Acute Exacerbations in High Risk COPD Patients.
    MPEX Pharmaceuticals
    Role: Principal Investigator
  • July 2007–April 2010
    A Randomized, Double-Blind, Placebo Controlled, Exploratory Study to Assess the Safety and Efficacy of Multiple Doses of ACZ885 in COPD Patients.
    Novartis
    Role: Principal Investigator
  • August 2003–July 2009
    Randomized double blind trial of the effect of Advair on bacterial colonization.
    Glaxo Smith Kline
    Role: Co-Investigator
    $96,000
  • January 2008–June 2009
    A Proof of Principle Randomized Controlled 8 Week Study of the Safety and Efficacy of the Lung Flute in Adults with Chronic Obstructive Pulmonary Disease a FDA 510(k) Equivalency Study.
    Role: Principal Investigator
    $144,000
  • June 2007–June 2009
    A Phase IIIB twelve month, double blind, double dummy, randomized, parallel group, multi-center exacerbation study of Symbicort PMDI and 80/4.5 compared to formeterol turbohaler in COPD subjects.
    Astra Zeneca Pharmaceuticals
    Role: Principal Investigator
  • June 2008–September 2008
    A Phase 1, Multicenter, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Solution for Inhalation Administered for 5 days to Chronic Bronchitis Patients.
    MPEX Pharmaceuticals
    Role: Principal Investigator
  • June 2007–June 2008
    A Randomized, Double-Blind, Double-Dummy, Parallel Group Trial Comparing 12 Weeks Treatment with Tiotropium Inhalation Capsules 18mcg Via the HandiHaler Once Daily to Combivent Inhalation
    Boehringer Ingelheim,
    Role: Principal Investigator
  • June 2005–June 2008
    A 6-Month Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Efficacy and Safety Study of Symbicort pMDI 2 X 160/4.5 ug
    Astra-Zeneca
    Role: Principal Investigator
  • May 2007–December 2007
    Genotyping Analysis of Streptococcus pneumoniae strains isolated from the PERSPECTIVE study.
    Sanofi-Aventis Pharmaceuticals
    Role: Co-Principal Investigator
    $60,000
  • June 2006–June 2007
    A Prospective Observational Study for the Psychometric Validation of a Patient Reported Questionnaire in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
    Glaxo Smith Kline
    Role: Principal Investigator
  • August 2004–June 2007
    A double blind, randomized, placebo controlled study to investigate intermittent pulse therapy of Moxifloxacin as a prevention of acute exacerbation of chronic bronchitis.
    Bayer Pharmaceuticals
    Role: Principal Investigator
  • January 2004–March 2006
    Comparison of sputum induction with the Lung Flute with hypertonic saline and sham flute in COPD.
    Role: Principal Investigator
  • September 2000–August 2005
    Haemophilus antigen regulation of inflammation in COPD.
    National Heart, Lung & Blood Institute
    Role: Principal Investigator
    $700,000
  • June 2004–May 2005
    A phase 2 placebo controlled randomized double blind study of the efficacy and safety of Tofimilast dry powder inhalation in COPD.
    Pfizer
    Role: Principal Investigator
  • May 2004–September 2004
    Comparison of sputum induction with the Lung Flute with hypertonic saline and sham flute in healthy adults.
    Medical Acoustics
    Role: Principal Investigator
  • October 2000–September 2004
    Quality of Life assessment in acute exacerbations of COPD.
    VA Research Enhancement
    Role: Principal Investigator
  • October 2000–September 2004
    Enhancing clinical research at the Buffalo VA.
    VA Research Enhancement
    Role: Co-Principal Investigator
  • November 2002–September 2003
    A trial of Tiotropium versus placebo assessing proportion of patients experiencing exacerbation and proportion of patients hospitalized with exacerbation of COPD.
    Role: Principal Investigator
  • May 2002–April 2003
    Comparison of sputum induction with the Lung Flute with hypertonic saline in patients with COPD.
    Medical Acoustics
    Role: Principal Investigator
    $15,000
  • May 2002–April 2003
    Sputum induction with the Lung Flute in healthy subjects.
    Medical Acoustics
    Role: Principal Investigator
  • July 2001–April 2003
    A phase 3 trial of comparative efficacy of Clarithromycin extended release and immediate release tablets in acute exacerbations of chronic bronchitis.
    Boehringer Ingelheim Pharmaceuticals
    Role: Principal Investigator
  • October 2000–March 2003
    Effect of amoxicillin/clavulanate on chronic lower respiratory tract inflammation in patients with chronic bronchitis.
    SmithKline Beecham Pharmaceuticals
    Role: Principal Investigator
  • October 1998–September 2001
    Quality of life in COPD: Impact of steroids and chronic inflammation.
    VA Research Enhancement
    Role: Principal Investigator
  • October 1998–September 2001
    Outer membrane protein B1 of Moraxella catarrhalis.
    VA Merit Review
    Role: Principal Investigator
    $161,400
  • October 1996–September 2000
    Bacterial infection in COPD.
    VA Merit Review
    Role: Co-Investigator
  • July 2000–June 2000
    Comparative study of Gemifloxacin vs Levofloxacin in acute exacerbations of chronic bronchitis.
    Glaxo Smith Kline
    Role: Principal Investigator
  • July 1999–June 2000
    Comparative study of Clarithromycin extended release vs Augmentin in acute exacerbations of chronic bronchitis
    Abbott
    Role: Principal Investigator
  • July 1999–June 2000
    Comparative study of Gemifloxacin vs Clarithromycin in acute exacerbations of chronic bronchitis.
    Glaxo Smith Kline
    Role: Principal Investigator
  • July 1998–May 1999
    Mucosal immunity to Moraxella catarrhalis.
    VA Research Enhancement
    Role: Principal Investigator
  • July 1995–July 1997
    Systemic corticosteroids in COPD exacerbations.
    VA Cooperative Studies,
    Role: Principal Investigator
    $20,000
  • October 1993–September 1996
    Bacterial infection in COPD.
    VA Merit Review
    Role: Co-Investigator
  • July 1993–June 1996
    Immune response to Moraxella catarrhalis in bronchiectasis.
    Buswell research fellowship
    Role: Principal Investigator
See all (35 more)
Patents:
  • Gene encoding outer membrane protein B1 of Moraxella catarrhalis.
  • Method for detecting bacterial exacerbations of chronic obstructive pulmona
  • Vaccine for Nontypeable H. influenzae infection.

Journal Articles:
  • Faner R., Sibila O., Agustí A., Bernascon E., Chalmers J.D., Huffnangle G., Manichanh C., Molyneaux P., Paredes R., Brocal V.P., Ponomarenko J., Sethi S, Dorca J., Monsó E.. The Microbiome in Respiratory Medicine: Current Challenges and Future Perspectives. European Respiratory Journal.. 2017; 49(4).
  • Chalmers J., Sethi S. Raising Awareness of Bronchiectasis in Primary Care: Overview of Diagnosis and Management Strategies in Adults. NPJ Primary Care Respiratory Medicine. 2017; 27(1).
  • Sharma S, Ryndak MB, Aggarwal AN, Yadav R, Sethi S, Masih S, Laal S, Verma I. Transcriptome analysis of mycobacteria in sputum samples of pulmonary tuberculosis patients PLoS One. 2017; 12(3).
  • Martinez F.J., Rabe K.F., Ferguson G.T., Fabbri L.M., Rennard S., Feldman G.J., Sethi S, Spangenthal S., Gottschlich G., Rodriguez-Roisin R., Arora S., Siler T.M., Siddiqui S., Darken P., Fischer T., Maes A., Golden M., Orevillo C., Reisner C.. Novel Co-Suspension glycopyrrolate/formoterol MDI combination for patients with COPD. CHEST. 2017; 151(2).
  • Sethi S, Fogarty C., Hanania N., Martinez F.J., Rennard S., Orevillo C., Darken P., St. Rose E., Strom S., Fisher T., Golden M., Dwivedi S., Reisner C.. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Dose-Ranging Study of Three Doses of Formoterol Fumurate Delivered by a Metered Dose Inhaler Employing Co-Suspension Delivery Technology and Two Doses of Open-Label Foradil Aerolizer in Patients. Chronic Obstructive Pulmonary Disease: Journal of the COPD Foundation,. 2017.
  • Linder D., Yin J.J., Rochani H., Samawi H.M., Sethi S. Reducing sample size and cost in clinical studies of association with count outcomes. (In press). Computational Statistics and Data Analysis.. 2017.
  • Sethi S, Mammen MJ. Microbiome in Chronic Lung Disease. Barcelona Respiratory Reviews. 2017; 3.
  • Provost K, Frederick CA, Sethi S. Bacterial infection.. Acute Exacerbations of Pulmonary Diseases (ERS Monograph), European Respiratory Society. 2017.
  • Martinez F.J., Rabe K.F., Sethi S, Pizzichini E., McIvor A., Anzueto A., Alagappan V.K., Siddiqui S., Rekeda L., Miller C.J., Zetterstrand S., Reisner C., Rennard S.I.. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2 -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 2016; 194(5).
  • Sethi S. Effects of Roflumilast in COPD Patients Receiving ICS/LABA Fixed-Dose Combination: RE2SPOND Rationale and Study Design. International Journal of COPD. 2016; 17(11).
  • Pettigrew MM, Tsuji BT, Gent JF, Kong Y, Holden PN, Sethi S, Murphy TF. Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease Antimicrob Agents Chemother. 2016; 60(7).
  • Sethi S. Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents and Chemotherapy. 2016; 60(7).
  • Damera G., Pham T.H., Zhang J., Ward C.K., Newbold P., Ranade K., Sethi S. A sputum proteomic signature that associates with increased IL-1β levels and bacterial exacerbations of COPD. Lung. 2016; 1943(3).
  • Behrsing H., Raabe H., Manuppello J., Bombick B., Curren R., Sullivan K., Sethi S, Phipps R., Tesfaigzi Y., Yan S., D'Ruiz C., Tarran R., Constant S., Phillips G., Gaça M., Hayden P., Cao X., Mathis C., Hoeng J., Braun A., Hill E.. Effects of Roflumilast in COPD Patients Receiving ICS/LABA Fixed-Dose Combination: RE2SPOND Rationale and Study Design. International Journal of COPD. 2016; 44(2).
  • Dy R., Sethi S. The lung microbiome and exacerbations of COPD. Current Opinion in Pulmonary Medicine. 2016; 22(3).
  • Martinez F.J., Fabbri L.M., Rennard S.I., Sethi S, Gottschlich G., Arora S., Darken P., Orevillo C., Siddiqui S., Reisner C.. Cardiovascular Safety Profile of a Novel LAMA/LABA Co-Suspension Technology Fixed-Dose Combination of Glycopyrrolate/Formoterol Delivered by Metered Dose Inhaler in Patients with COPD: 24-Hour Holter Monitoring Study. ATS International Conference, San Francisco, CA, May 2016.. 2016.
  • Dy R., Wrona C., Murphy TF, Sethi S. Airway Inflammatory Mediator Determinants of COPD Exacerbation Severity and Resolution. ATS International Conference, San Francisco, CA. 2016.
  • Tariq A., Wrona C., Sethi S. Differential Induction of MUC5AC Mucin Gene Expression by Haemophilus spp. Isolated from Patients with COPD. ATS International Conference, San Francisco, CA. 2016.
  • Tunsupon P., Smith M., Wrona C., Sethi S. Sputum Secretory Immunoglobulin A1 (SIgA1) from Patients with COPD Enhances Opsonophagocytosis of Nontypeable Haemophilus influenzae and Moraxella catarrhalis. ATS International Conference, San Francisco, CA. 2016.
  • Mustafa B., Wrona C., Murphy TF, Sethi S. Change in Titer of Serum Antibodies Directed at the Bacterial Surface Reflect the Frequency of Lower Airway Bacterial Carriage and Infection in COPD. ATS International Conference, San Francisco, CA. 2016.
  • Sethi S. Antibiotic resistance: challenges and successes in respiratory infection. Future Microbiology. 2016; 11.
  • Berenson CS, Kruzel RL, Sethi S. The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD Immunol Invest. 2016; 45(2).
  • Sethi S, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Wilson R. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease Infection. 2016; 44(1).
  • Roos AB, Sethi S, Nikota J, Wrona CT, Dorrington MG, Sandén C, Bauer CM, Shen P, Bowdish D, Stevenson CS, Erjefält JS, Stampfli MR. Interleukin-17A Promotes Neutrophilia in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Am J Respir Crit Care Med. 2015.
  • Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD Eur Respir Rev. 2015; 24(136).
  • Wilson R, Anzueto A, Miravitlles M, Arvis P, Haverstock D, Trajanovic M, Sethi S. Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD Int J Chron Obstruct Pulmon Dis. 2015; 10.
  • Crisafulli E., Torres A., Huerta A., Mendez R., Guerrero M., Martinez R., Soler N., Sethi S, Menendez R.. C- reactive protein at discharge, Diabetes mellitus and ≥ 1 prior hospitalization Predict Early Readmission in patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. COPD. 2015; 12(3).
  • Celli B.R., Decramer M., Wedzicha J.A., Wilson K.C., Agustí A., Criner G.J., MacNee W., Make B.J., Rennard S.I., Stockley R.A., Vogelmeier C., Anzueto A., Au D.H., Barnes P.J., Burgel P.R., Calverley P.M., Casanova C., Clini E.M., Cooper C.B., Coxson H.O., Dusser D.J., Fabbri L.M., Fahy B., Ferguson G.T., Fisher A., Fletcher M.J., Hayot M., Hurst J.R., Jones P.W., Mahler D.A., Maltais F., Mannino D.M., Martinez M.J., Miravitlles M., Meek P.M., Papi A., Rabe K.F., Roche N., Sciurba F.C., Sethi S, Siafakas N., Sin D.D., Soriano J.B., Stoller J.K., Tashkin D.P., Troosters T., Verleden G.M., Verschakelen J., Vestbo J., Walsh J.W., Washko G.R., Wise R.A., Wouters E.F., ZuWallack R.L.. ATS/ERS Task Force for COPD Research. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. European Respiratory Review. 2015; 24(136).
  • Crisafulli E., Torres A., Huerta A., Mendez R., Guerrero M., Martinez R., Soler N., Sethi S, Menendez R.. C- reactive protein at discharge, Diabetes mellitus and ≥ prior hospitalization Predict Early Readmission in patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. COPD. 2015; 12(3).
  • Murphy TF, Kirkham C, Jones MM, Sethi S, Kong Y, Pettigrew MM. Expression of IgA Proteases by Haemophilus influenzae in the Respiratory Tract of Adults With Chronic Obstructive Pulmonary Disease. J Infect Dis. 2015; 212(11).
  • Celli B.R., Decramer M., Wedzicha J.A., Wilson K.C., Agustí A., Criner G.J., MacNee W., Make B.J., Rennard S.I., Stockley R.A., Vogelmeier C., Anzueto A., Au D.H., Barnes P.J., Burgel P.R., Calverley P.M., Casanova C., Clini C.M., Cooper C.B., Coxson H.O., Dusser D.J., Fabbri L.M., Fahy B., Ferguson G.T., Fisher A., Fletcher M.J., Hayot M., Hurst J.R., Jones P.W., Mahler D.A., Maltais F., Mannino D.M., Martinez M.J., Miravitlles M., Meek P.M., Papi A., Rabe K.F., Roche N., Sciurba F.C., Sethi S, Siafakas N., Sin D.D., Soriano J.B., Stoller J.K., Tashkin D.P., Troosters T., Verleden G.M., Verschakelen J., Vestbo J., Walsh J.W., Washko G.R., Wise R.A., Wouters E.F., ZuWallack R.L.. ATS/ERS Task Force for COPD Research. An Official ATS/ERS Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2015.
  • Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL. ATS/ERS Task Force for COPD Research. An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2015; 191(7).
  • Mohan A., Sethi S. What is “bacterial colonization” in COPD?. European Respiratory Society Monograph. 2015; 69.
  • Parameswaran GI, Sethi S. Long term Macrolide therapy in Chronic Obstructive Pulmonary Disease.. Canadian Medical Association Journal. 2014; 186(15).
  • Provost K, Smith M, Arold SP, Hava DL, Sethi S. Calcium Restores the Macrophage Response to Non-typeable Haemophilus influenzae in COPD. Am J Respir Cell Mol Biol. 2014.
  • Berenson CS, Kruzel R., Eberhardt E., Dolnick R., Minderman H., Wallace P., Sethi S. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations Thorax. 2014; 69(9).
  • Huang Y.J., Sethi S, Murphy TF, Nariya S., Boushey H.A., Lynch S.V.. Airway Microbiome dynamics in exacerbations of chronic obstructive pulmonary disease.. Journal of Clinical Microbiology. 2014; 52(8).
  • Fitzpatrick ME, Sethi S, Daley CL, Ray P, Beck JM, Gingo MR. Infections in "noninfectious" lung diseases. Ann Am Thorac Soc. 2014; 11 Su.
  • Kalathil SG, Lugade AA, Pradhan V, Miller A, Parameswaran GI, Sethi S, Thanavala Y, Parameswaran G. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014; 190(1).
  • Kalathil S.G., Lugade A.A., Pradhan V., Miller A., Parameswaran GI, Sethi S, Thanavala Y. T regulatory cells and PD-1 T cells contribute to effector T cell dysfunction in COPD patients.. American Journal of Respiratory and Critical Care Medicine. 2014; 190(1).
  • Kalathil S.G., Lugade A.A., Pradhan V., Miller A., Parameswaran GI, Sethi S, Thanavala Y.. T regulatory cells and PD-1 T cells contribute to effector T cell dysfunction in COPD patients. American Journal of Respiratory and Critical Care Medicine. 2014; 190(1).
  • Leidy N.K., Sexton C.C., Jones P.W., Monz B.U., Nelsen L., Goldman M., Murray L.T., Sethi S. Measuring Respiratory Symptoms in Clinical Trials of COPD: Reliability, Validity, and Responsiveness of a Daily Diary.. Thorax. 2014; 69(5).
  • Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014; 11(3).
  • Rangelov K, Sethi S. Role of infections. Clin Chest Med. 2014; 35(1).
  • Mohan A, Sethi S. The reliability and validity of patient-reported chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med. 2014; 20(2).
  • Leidy N.K., Murray L.T., Jones P., Sethi S. Performance of the EXACT Patient-Reported Outcome (PRO) Measure in Three Clinical Trials of COPD. Annals of the American Thoracic Society. 2014; 11(3).
  • Desai H., Eschberger K., Wrona C., Grove L., Agrawal A., Grant B., Yin J., Parameswaran GI, Murphy TF, Sethi S. Bacterial Colonization of the Lower Respiratory Tract Increases Daily Symptoms in Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society. 2014; 11(3).
  • Tu C., Mammen MJ, Li J., Shen X., Jiang X., Hu Q., Wang J., Sethi S, Qu J.. Current based Proteomics Investigation of Bronchoalveolar Lavage Fluid in Chronic Obstructive Pulmonary Disease Patients. Journal of Proteome Research. 2014; 13(2).
  • Tu C, Mammen MJ, Li J, Shen X, Jiang X, Hu Q, Wang JJ, Sethi S, Qu J. Large-Scale, Ion-Current-Based Proteomics Investigation of Bronchoalveolar Lavage Fluid in Chronic Obstructive Pulmonary Disease Patients. J Proteome Res. 2014; 13(2).
  • Sethi S. Chronic obstructive pulmonary disease and infection. Disruption of the microbiome? Ann Am Thorac Soc. 2014; 11 Su.
  • Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXACT Patient-Reported Outcome (PRO) Measure in Three Clinical Trials of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2014.
  • Desai H, Eschberger K, Wrona C, Grove L, Agrawal A, Grant B, Yin J, Parameswaran GI, Murphy T, Sethi S. Bacterial Colonization Increases Daily Symptoms in Patients with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2014.
  • Fitzpatrick M.E., Sethi S, Daley C.L., Ray P., Beck J.M., Gingo M.R.. Infections in Noninfectious Lung Diseases.. Annals of the American Thoracic Society. 2014; Sup(4).
  • Sethi S, Yin J.J., Anderson P.. Lung Flute improves Symptoms and Health Status in COPD with Chronic Bronchitis: A 26 week Randomized Controlled Trial. Clinical and Translational Medicine. 2014; 3(29).
  • Sethi S. Lower Airway Bacteria in COPD: Differentiating True Colonization, Chronic Infection and Acute Infectious Exacerbations.. Respiratory Drug Delivery. 2014; 1.
  • Wilson R, Sethi S, Anzueto A, Miravitlles M. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease. J Infect. 2013; 67(6).
  • Sethi S, Nag N. A 5-day course of systemic corticosteroids is adequate to treat acute exacerbations of chronic obstructive pulmonary disease. Evid Based Med. 2013.
  • Eutsey R.A., Hiller N.L., Earl J.P., Janto B.A., Dahlgren M.E., Ahmed A., Powell E., Schultz M.P., Gilsdorf J.R., Zhang L., Smith A., Murphy TF, Sethi S, Shen K., Post J.C., Hu F.Z., Ehrlich G.D.. Design and validation of a supragenome array for determination of the genomic content of Haemophilus influenzae isolates. BMC Genomics. 2013; 14.
  • Sethi S. Chronic bronchial infection/colonisation: aetiology and mechanisms. The spectrum of bronchial infection.. European Respiratory Monograph. 2013; 60.
  • Berenson CS, Desai H., Eberhardt E., Sethi S. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease.. Journal of Infectious Diseases. 2013; 208(12).
  • Sethi S. Chance favors the prepared mind.. American Journal of Respiratory and Critical Care Medicine. 2012; 186(11).
  • Sethi S, Mahler D.A., Marcus P., Owen C.A., Yawn B., Rennard S.. Inflammation in COPD: Implications for Management.. American Journal of Medicine. 2012; 125(12).
  • Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiology.. 2012.
  • Wilson R., Anzueto A., Miravittles M., Arvis P., Alder J., Haverstock, Sethi S. Moxifloxacin vs. Amoxicillin/clavulanic acid in outpatient AECOPD: MAESTRAL results.. European Respiratory Journal. 2012; 40(1).
  • Han M.K., Huang Y.J., Lipuma J.J., Boushey H.A., Boucher R.C., Cookson W.O., Curtis J.L., Erb-Downward J., Lynch S.V., Sethi S, Toews G.B., Young V.B., Wolfgang M.C., Huffnagle G.B., Martinez F.J.. Significance of the microbiome in obstructive lung disease.. Thorax. 2012; 67(5).
  • Sansgiry S.S., Joish V.N., Boklage S., Goyal R., Chopra P., Sethi S. Economic Burden of Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.. Journal of Medical Economics. 2012; 15(2).
  • Mammen MJ, Sethi S. Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease. Polish Archives of Internal Medicine. 2012; 122(1-2).
  • Jones P.W., Chen W.H., Wilcox T.K., Sethi S, Leidy. Characterizing and Quantifying the Symptomatic Features of COPD Exacerbations, for the EXACT-PRO Study Group.. Chest. 2011; 139(6).
  • Murphy TF, Lesse AJ, Kirkham C, Zhong H, Sethi S, Munson RS. A Clonal Group of Nontypeable Haemophilus influenzae with Two IgA Proteases Is Adapted to Infection in Chronic Obstructive Pulmonary Disease. PLoS One. 2011; 6(10).
  • Parameswaran GI, Sethi S, Murphy TF. Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD. Chest. 2011; 140(3).
  • Sethi S, Criner G.J., Evans R.M., Hanania N.A.. Exacerbations of Chronic Obstructive Pulmonary Disease.. AMA Therapeutic Insights. 2011.
  • Sethi S, Leidy N.K., Wilcox T.K., Jones P.W., Roberts L., Powers J.H.. Standardizing Measurement of COPD Exacerbations: Reliability and Validity of a Patient-Reported Diary for the EXACT-PRO Study Group.. American Journal of Respiratory and Critical Care Medicine. 2011; 183(3).
  • Parameswaran GI, Sethi S, Murphy TF, Parameswaran G. Effects of bacterial infection on airway antimicrobial peptides and proteins in chronic obstructive pulmonary disease. Chest. 2011.
  • Nakamura S, Shchepetov M, Dalia AB, Clark SE, Murphy TF, Sethi S, Gilsdorf JR, Smith AL, Weiser JN. Molecular basis of increased serum resistance among pulmonary isolates of non-typeable Haemophilus influenzae. PLoS Pathog. 2011; 7(1).
  • Clauss M., Voswinckel R., Rajashekhar G., Sigua N.L., Fehrenbach H., Rush N.I., Schweitzer K.S., Yildirim A.O., Kamocki K., Fisher A.J., Gu Y., Safadi B., Nikam S., Hubbard W.C., Tuder R.M., Twigg H.L., Presson R.G., Sethi S, Petrache I.. Lung endothelial monocyte-activating protein 2 is a mediator of cigarette smoke-induced emphysema in mice.. Journal of Clinical Investigation.. 2011; 121(6).
  • Harvey C.J., Thimmulappa R.K., Sethi S, Kong X., Yarmus L., Brown R.H., Feller-Kopman D., Wise R., Biswal S.. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.. Science Translational Medicine. 2011; 3(78).
  • Sethi S, Cote C.. Bronchodilator combination therapy for COPD.. Current Clinical Pharmacology.. 2011; 6(1).
  • Moghaddam S.J., Ochoa C. E., Sethi S, Dickey B.F.. Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer.. International Journal of COPD. 2011; 6.
  • Sethi S, Berim I. The benefits of long-term systemic antimicrobial therapy in Chronic Obstructive Pulmonary Disease.. Therapeutic Advances in Respiratory Disease. 2011; 5(3).
  • Sethi S. Management of COPD.. AMA Therapeutic Insights. 2011.
  • Murphy TF, Lesse AJ, Kirkham C., Zhong H., Sethi S, Munson Jr. R.S.. A Clonally Related Group of Nontypeable Haemophilus influenzae Adapted to Infection in Chronic Obstructive Pulmonary Disease.. PLoS ONE. 2011; 6(10).
  • Wilson R., Anzueto A., Miravittles M., Arvis P., Farago G., Haverstock D., Trajanovic M., Sethi S. A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTREL methodology.. International Journal of COPD. 2011; 6.
  • Sethi S. Molecular Diagnosis of Respiratory Tract Infection in Acute exacerbations of Chronic Obstructive Pulmonary Disease.. Clinical Infectious Disease. 2011; 52(Supp).
  • Desai H., Richter S., Doern G., Heilmann K., Dohrn C., Johnson A., Brauer A., Murphy TF, Sethi S. Antibiotic resistance in Sputum Isolates of Streptococcus pneumoniae in Chronic Obstructive Pulmonary Disease is related to antibiotic exposure.. Journal of COPD.. 2010; 7(5).
  • Sethi S, Bartlett J., Evans R.M., Niederman M.S., Tan L..J.. Community Acquired Pneumonia.. AMA Therapeutic Insights. 2010.
  • Sethi S, Jones P.W., Theron M.S., Miravitlles M., Rubinstein E., Wedzicha J.A., Wilson R. PULSE Study group. Pulsed Moxifloxacin for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease: a randomized controlled trial. Respiratory Research. 2010; 28,11(10).
  • Sethi S. Antibiotics in acute exacerbations of chronic bronchitis. Expert Reviews on Anti- Infective Therapy.. 2010; 8(4).
  • Sethi S. Infection as a Comorbidity of COPD. European Respiratory Journal. 2010; 35(6).
  • Sethi S. Pulsed Moxifloxacin for the Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease: a randomized controlled trial.. Respiratory Research. 2010.
  • Sethi S. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): Qualitative Methods and Content Validity.. Value in Health. 2010; 13(8).
  • Novotny LA, Adams LD, Kang DR, Wiet GJ, Cai X, Sethi S, Murphy TF, Bakaletz LO. Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine. 2009.
  • LaFontaine ER, Snipes LE, Bullard B, Brauer AL, Sethi S, Murphy TF. Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis. Clin Vaccine Immunol. 2009; 16(5).
  • Gaschler GJ, Skrtic M, Zavitz CC, Lindahl M, Onnervik PO, Murphy TF, Sethi S, Stämpfli MR. Bacteria challenge in smoke-exposed mice exacerbates inflammation and skews the inflammatory profile. Am J Respir Crit Care Med. 2009; 179(8).
  • Sethi S. The Use of Moraxella catarrhalis Lipooligosaccharide Mutants to Identify Specific Oligosaccharide Epitopes Recognized by Human Serum Antibodies.. Infection Immunity. 2009; 77(10).
  • Sethi S. . Pseudomonas aeruginosa population biology in COPD.. Journal of Infectious Diseases. 2009; 200(12).
  • Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in COPD.. BMC Infectious Diseases. 2009.
  • Sethi S; Mallia P and S Johnston. New paradigms in COPD pathogenesis II.. Proceedings of the American Thoracic Society. 2009; 6(6).
  • Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(22).
  • Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S. Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2008.
  • Sethi S. Optimizing antibiotic therapy for acute exacerbations of COPD.. International Journal of COPD. 2008; 3(1).
  • Sethi S. Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quntities of the HMW1 and HMW2 adhesins. Infection Immunity. 2008; 76(10).
  • Sethi S,Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, Wouters E, and CB Cooper. COPD as a Lung Disease With Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention.. COPD: Journal of Chronic Obstructive Pulmonary Disease 5. 2008; 5(4).
  • Sethi S,Bartlett J. Diagnosis and treatment of infection in acute exacerbations of chronic obstructive pulmonary disease. UpToDate. 2008.
  • Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF. Inflammatory Profile of New Bacterial Strain Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2007.
  • Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007; 4(7).
  • Sethi S, File T., Dagan R.. Acute exacerbations of chronic bronchitis: diagnosis and therapy.. Journal of Respiratory Diseases. 2007.
  • Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176(4).
  • Murphy TF, Brauer AL, Sethi S, Kilian M, Cai X, Lesse AJ. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis. 2007; 195(1).
  • Fernaays MM, Lesse AJ, Sethi S, Cai X, Murphy TF. Differential genome contents of nontypeable Haemophilus influenzae strains from adults with chronic obstructive pulmonary disease. Infect Immun. 2006; 74(6).
  • Niederman M.S., Anzueto A., Sethi S, Choudhri S., Kureishi A., Haverstock D., Perroncel R.. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.. Respiratory Medicine. 2006; 174(1).
  • Berenson CS, Maloney J., Grove L., Wrona C., Sethi S. Impaired Alveolar Macrophage Response to Haemophilus Antigens in Chronic Obstructive Lung Disease.. Journal of Respiratory and Critical Care Medicine. 2006; 174(1).
  • Veeramachaneni S., Sethi S. Pathogenesis of bacterial exacerbations of COPD.. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2006; 3(2).
  • Adlowitz D., Kirkham, C., Sethi S, Murphy TF. Human Serum and Mucosal Antibody Responses to Outer Membrane Protein G1b of Moraxella catarrhalis in Chronic Obstructive Pulmonary Disease.. FEMS Immunology. 2006; 46(1).
  • Eldika, N., Sethi S. Role of Nontypeable Haemophilus influenzae in exacerbations and progression of COPD.. Current Opinion in Pulmonary Medicine. 2006; 12(2).
  • Sethi S, Maloney J., Grove L., Wronta C.T., Berenson CS. Airway inflammation and bronchial bacterial colonization in ex-smokers with COPD.. American Journal of Respiratory and Critical Care Medicine. 2006; 173(9).
  • Look D.C., Chin C.L., Manzel L.J., Lehman E.E., Humlicek A.L., Shi L., Starner T.D., Denning G.M., Murphy TF, Sethi S. Modulation of airway inflammation by Haemophilus influenzae isolates associated with chronic obstructive pulmonary disease exacerbation.. Proceedings of the American Thoracic Society. 2006; 3(6).
  • Berenson CS, Garlipp M.A., Grove L.L., Maloney J., Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease.. Journal of Infectious Disease. 2006; 194(10).
  • Murphy TF, Brauer A., Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease, dynamics of carriage and immune responses. American Journal of Respiratory and Critical Care Medicine. 2005; 172(2).
  • Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease.. Clinical Infectious Diseases. 2005; 15(41).
  • Murphy TF, Kirkham C, Sethi S, Lesse AJ. Expression of a peroxiredoxin-glutaredoxin by Haemophilus influenzae in biofilms and during human respiratory tract infection. FEMS Immunol Med Microbiol. 2005; 44(1).
  • Sethi S, Anzueto A, Farrell D.J.. Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis.. Annals of Clinical Microbiology and Antimicrobials. 2005; 4(1).
  • Sethi S, Breton J., Wynne B.. The efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate, 2000/125mg twice daily for 5 days, versus amoxicillin/clavulanate, 875/125mg twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrobial Agents and Chemotherapy. 2005; 49(1).
  • Berenson CS, Murphy TF, Wrona, C.T., Sethi S. Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage cytokines. Infection and Immunity. 2005; 73(5).
  • Murphy TF, Brauer A.L., Aebi C., Sethi S. Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease.. Infection and Immunity. 2005; 73(6).
  • Sethi S. Pathogenesis and treatment of acute exacerbations of COPD.. Seminars in Respiratory and Critical Care Medicine. 2005; 26(2).
  • Adlowitz D., Sethi S, Adler B., Cullen, P., Murphy TF. Human Antibody Response to Outer Membrane Protein G1a, a Lipoprotein of Moraxella catarrhalis.. Infection and Immunity. 2005; 73(10).
  • Murphy TF, Brauer, A.L., Adler, B., Sethi S. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease.. Infection and Immunity. 2005; 73(12).
  • Chin C.L., Manzel L.J., Lehman E.E., Humlicek, A.L., Shi L., Starner T.D., Denning G.M., Murphy TF, Sethi S, Look D.C.. Haemophilus influenzae from patients with COPD exacerbation induce more inflammation than colonizers.. American Journal of Respiratory and Critical Care Medicine. 2005; 172.
  • Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infect Dis Clin North Am. 2004; 18(4).
  • Sethi S, File TM. Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem. Curr Med Res Opin. 2004; 20(10).
  • Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170(3).
  • Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis. 2004; 17(2).
  • Sethi S, Wrona C, Grant BJ, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 169(4).
  • Sethi S. Bacteria in exacerbations of COPD: Phenomenon or epiphenomenon. Proceedings of the American Thoracic Society. 2004; 1.
  • Sethi S. Gatifloxacin in community-acquired respiratory tract infection. Expert Opin Pharmacother. 2003; 4(10).
  • Sethi S. The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Current Infectious Disease Reports. 2003; 5.
  • Sethi S, Dagan, R.. Acute exacerbations of chronic bronchitis: Diagnosis and therapy. Respiratory Diseases. 2003; 24(6).
  • MURPHY TF. Horizontal transfer of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae in a patient with chronic obstructive pulmonary disease.. Journal of Infectious Diseases. 2003; 188.
  • MURPHY TF. Human immune response to outer membrane protein CD of Moraxella catarrhalis in adults with chronic obstructive pulmonary disease.. Infection and Immunity. 2003; 71.
  • Abe Y, Murphy TF, Sethi S, Faden HS, Dmochowski J, Harabuchi Y, Thanavala YM. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 165(7).
  • Sethi S. Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. Geriatrics. 2002; 57(3).
  • Bakri F, Brauer AL, Sethi S, Murphy TF. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbationsof chronic obstructive pulmonary disease. J Infect Dis. 2002; 185(5).
  • Hiltke TJ, Sethi S, Murphy TF. Sequence stability of the gene encoding outer membrane protein P2 of nontypeableHaemophilus influenzae in the human respiratory tract. J Infect Dis. 2002; 185(5).
  • Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.. New England Journal of Medicine. 2002; 347(7).
  • Sethi S. Efficacy of antibiotics in acute exacerbations: A review of the literature. Consultant. 2002; 42.
  • Sethi S. Acute exacerbations of COPD: A "multi-pronged" approach. Respiratory Diseases. 2002; 23.
  • Murphy TF, Sethi S. Chronic obstructive pulmonary disease: Role of bacteria and guide to antibacterial selection in the older patient. Drugs and Aging. 2002; 19.
  • Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001; 14(2).
  • Obaji, A., & Sethi S.. Acute exacerbations of chronic bronchitis: What role the new fluoroquinolones?. Drugs and Aging. 2001; 18.
  • Sheikh, S., & Sethi S.. Management of infectious excerbation of COPD. Home Health Care Consultant. 2001; 8.
  • Sethi S.. Antibiotics and acute exacerbation of COPD. Advance for Managers of Respiratory Care. 2001; 10(8).
  • Fendrick, A.M., Saint, S., Brook, I., Jacobs, M.R., Pelton, S., Sethi S. Diagnosis and treatment of upper repiratory tract infections in the primary care setting. Clinical Therapeutics. 2001; 23.
  • Sethi S. Pericolo di infiammazione. Le infezioni broncopolmonari. Ricera Roche (Italian). 2000.
  • Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis.. Chest. 2000; 118(6).
  • Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerbations of COPD. A constructive view. Chest. 2000; 118(1).
  • Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000; 117(5 Sup).
  • Sethi S. Bacterial infection and the pathogenesis of COPD. Chest. 2000; 117(5 Sup).
  • Sethi S., Muscarella, K.A., Evans, N., Klingman, K.L., & Murphy, T.F.. Acute bacterial exacerbations of COPD are associated with greater airway inflammation than non-bacterial exacerbations. Chest. 2000; 118.
  • Murphy TF, Kirkham C, DeNardin E, Sethi S. Analysis of antigenic structure and human immune response to outer membraneprotein CD of Moraxella catarrhalis. Infect Immun. 1999; 67(9).
  • Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV. Simultaneous respiratory tract colonization by multiple strains of nontypeablehaemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy. J Infect Dis. 1999; 180(2).
  • Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother. 1999; 43 Su.
  • Sethi S. Etiology & management of infections in COPD. Clinical Pulmonary Medicine. 1999; 6(6).
  • Sethi S. Is chronic bronchitis an infectious disease?. Mediguide to Pulmonary Medicine. 1998; 5(1).
  • Sethi S. Management of acute exacerbations of chronic bronchitis. Infectious Diseases in Clinical Practice. 1998; 7.
  • Yi K, Sethi S, Murphy TF. Human immune response to nontypeable Haemophilus influenzae in chronic bronchitis. J Infect Dis. 1997; 176(5).
  • Sethi S, Surface JM, Murphy TF. Antigenic heterogeneity and molecular analysis of CopB of Moraxella (Branhamella)catarrhalis. Infect Immun. 1997; 65(9).
  • Bhushan R, Kirkham C, Sethi S, Murphy TF. Antigenic characterization and analysis of the human immune response to outermembrane protein E of Branhamella catarrhalis. Infect Immun. 1997; 65(7).
  • Sethi S., Murphy, T.F., & Klingman, K.L.. Diagnosis, epidemiology & pathogenesis of bacterial infection in the molecular era. Clinical Pathology:Molecular Pathology. 1996; 49.
  • Hsiao CB, Sethi S, Murphy TF. Outer membrane protein CD of Branhamella catarrhalis: sequence conservation in strains recovered from the human respiratory tract. Microb Pathog. 1995; 19(4).
  • Sethi S, Hill SL, Murphy TF. Serum antibodies to outer membrane proteins (OMPs) of Moraxella (Branhamella)catarrhalis in patients with bronchiectasis: identification of OMP B1 as an important antigen. Infect Immun. 1995; 63(4).
  • Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992; 146(4).
See all (161 more)
Books and Book Chapters:
  • Parameswaran GI, Sethi S. Viral Pneumonia (book chapter). Clinical Respiratory Medicine. 2012.
  • Berim I., Sethi S. Community acquired pneumonia (book chapter). Clinical Respiratory Medicine. 2012.
  • Sethi S. Acute Exacerbations of COPD.. 2011.
  • Sethi S. Fungal infections. 2011.
  • Sethi S ; Desai H. Exacerbations of Chronic Obstructive Pulmonary Disease. 2010.
  • Sethi S ;Desai H. Humoral and Pulmonary Defenses against Respiratory Infections in COPD Patients.. 2010.
  • Sethi S. Infectious etiologies in acute exacerbations of COPD. Book chapter in Therapeutic Strategies in Acute Exacerbations of COPD.. 2009.
  • Sethi S. Treating and preventing Infections, book chapter in Clinical Management of Chronic Obstructive Pulmonary Disease.. Clinical management of chronic obstructive pulmonary disease. 2008.
  • Sethi S. Bacterial infection, book chapter in Chronic Obstructive Lung Diseases 2nd Edition.. Chronic Obstructive Lung Diseases. 2008.
  • Sethi S;Desai H.. Do airway bacteria cause COPD exacerbations? Book Chapter in Acute Exacerbations of COPD.. 2008.
  • Sethi S. Antibiotics. Book Chapter in Asthma and COPD, 2nd Edition. 2008.
  • Sethi S. Bacteria, Book chapter in Chronic Obstructive Pulmonary Disease.. Chronic Obstructive Pulmonary Disease. 2007.
  • Sethi S, Blasi F.. Antibiotics allergy in a COPD patient with frequent bacterial exacerbations. Book Chapter in Clinical Challenges in COPD.. Clinical Challenges in COPD. 2007.
  • Sethi,S./author of chapter Editors: Voelkel, N.F. & MacNee, W. Publisher: B.C. Decker, Inc.. Bacterial Infection, book chapter in Chronic Obstructive Lung Diseases.. Book Chapter in Chronic Obstructive Lung Disease. 2001.
See all (4 more)
Abstracts:
  • Kraskovsky V., Smith M., Sethi S, Provost K. Differences in COPD blood monocyte populations do not affect maturation to mature tissue macrophage by ex-vivo GMCSF. ATS International Conference, San Francisco, CA. 2016.
  • Roos A., Nikota J.K., Bjermer L.H., Bauer C.M., Stevenson C.S., Sethi S, Erjefalt J.S., Stampfli M.R.. IL-17A is Increased in Advanced COPD and During AECOPD. ATS International Conference, Denver, CO. 2015.
  • Rennard S.I., Martinez F.J., Sethi S, Zhu H., Haberman R., Zovko E.. Effects of Roflumilast in COPD Patients Receiving ICS/LABA Fixed-Dose Combination: Rationale and Design of a Prospective Randomized Controlled Trial. ATS International Conference, Denver, CO. 2015.
  • Sethi S, Kim J., Wrona C., Eberhardt E., Grove L., Murphy TF. Distinguishing Infecting (New) from Colonizing (Pre-Existing) Nontypeable Haemophilus Influenzae and Moraxella Catarrhalis Strains at Exacerbation of COPD by Molecular and Immunological Assay. ATS International Conference, Denver, CO. 2015.
  • Ray AD, Dhillon SS, Mohan A., Mahoney MC, Hutson AD, Hershberger P., Sethi S, Reid M.. Vitamin D is Inversely Associated with Body Mass Index and Smoking Status in COPD. ATS International Conference, Denver, CO. 2015.
  • Calverley P.M., Sethi S, Dawson M., Ward C., Newbold P., Van Der Merwe R.. A Phase 2 Study of MEDI8968, an Anti-Interleukin-1 Receptor I (IL-1RI) Monoclonal Antibody, in Adults with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease. ATS International Conference, Denver, CO. 2015.
  • Majumdar S., Wrona C., Sethi S. Host and Bacterial Proteases Contribute to the Proteolysis of Sputum Secretory IgA (sIgA) in COPD Exacerbations. ATS International Conference, Denver, CO. 2015.
  • Majumdar S., Wrona C., Sethi S. Proteolysis of Sputum Secretory IgA in Bacterial Exacerbations of COPD. ATS International Conference, Denver, CO. 2015.
  • Provost K, Smith M., Mohan A., Sahib K., Conway S., Sethi S. The Epidemiologic Burden of Streptococcus Pneumoniae Colonization and Infection in Chronic Obstructive Pulmonary Disease. ATS International Conference, Denver, CO. 2015.
  • Mohan A., Dhillon SS, Herschberger P., Mahoney MC, Reid M., Sethi S. Marked Seasonal Variability Can Affect Vitamin D Deficiency Prevalance in Veterans with Chronic Obstructive Pulmonary Disease. ATS International Conference, Denver, CO. 2015.
  • Rangelov K., Butkowski O., Wrona C., Woodruff P.G., Dransfield M.T., Sethi S. Chronic Azithromycin Use In COPD Is Associated With Reduction In Serum Antibodies To Nontypeable Haemophilus Influenzae. ATS International Conference, San Diego, CA. 2014.
  • Mohan A., Eberhardt E., Grove L., Murphy TF, Parameswaran GI, Sethi S. Clinical Features Of Exacerbations Of Chronic Obstructive Pulmonary Disease Are Related To Sputum Microbiology. ATS International Conference, San Diego, CA. 2014.
  • Burns K., Wrona C., Grove L., Eberhardt E., Sethi S. New Strain Acquisition Of Citrobacter spp And Stenotrophomonas spp In COPD Is Not Associated With Exacerbations. ATS International Conference, San Diego, CA. 2014.
  • Huang Y.J., Sethi S, Murphy TF, Nariya S., Boushey H.A., Lynch S.V.. Bacterial Airway Microbiome Dynamics In Exacerbations Of Chronic Obstructive Pulmonary Disease. ATS International Conference, San Diego, CA. 2014.
  • Bowman S., Pang B., Swords W., Anderson P., Grove L., Wrona C., Sethi S. Molecular and Microscopic detection of Nontypeable Haemophilus influenzae and Pseudomonas aeruginosa Biofilms in COPD sputa. ATS International Conference, Philadephia, PA. 2013.
  • Mammen MJ, Tu, Chengjian, Qu, Jun, Sethi S. Pathway Analysis Of Bronchoalveolar Lavage Fluid Proteome Of Individuals With COPD Compared To Healthy Controls. American Journal of Respiratory and Critical Care Medicine. 2013; 187.
  • Parameswaran GI, Sethi S, Willet A., Wrona C.. Nontypeable Haemophilus influenzae induces excessive TLR2 driven NF-kb activation in COPD airway epithelial cells. ATS International Conference, Philadephia, PA. 2013.
  • Mammen MJ, Tu C., Qu S., Sethi S. Pathway analysis of bronchoalveolar lavage fluid proteome of individuals with COPD compared to healthy controls. ATS International Conference, Philadephia, PA. 2013.
  • Provost K, Smith M., Arold S.P., Hava D.L., Sethi S. Extracellular Calcium augments the innate immune response of monocyte derived macrophages to bacterial challenge in patients with COPD by augmenting pattern recognition receptor expression. ATS International Conference, Philadephia, PA. 2013.
  • Bowman S., Yin J., Grove L., Wrona C., Sethi S. COPD exacerbation associated strains of Nontypeable Haemophilus influenzae form greater flow cell biofilms than colonizing strains. ATS International Conference. 2013.
  • Parameswaran GI, Sethi S, Willet A., Lesse AJ. Methicillin-Resistant Staphylococcus aureus (MRSA) in COPD. ATS International Conference, Philadephia, PA. 2013.
  • Wilson A., Anzueto A., Miravitlles M., Arvis P., Haverstock D., Trajanovic M., Sethi S. Prognostic factors for short and long term outcomes of outpatient exacerbations in moderate-to-severe COPD. European Respiratory Society Annual Congress, Vienna, Austria. 2012.
  • Mammen MJ, Qu J, Sethi S. Comprehensive Proteomic Profiling Of Bronchoalveolar Lavage Fluid Of Individuals With COPD Compared To Healthy Controls. American Journal of Respiratory and Critical Care Medicine. 2012; 185.
  • Berim I., Wrona C., Eberhardt E., Berenson CS, Palaniyar N., Sethi S. Relationship Of Bronchoalveolar Lavage Levels Of Surfactant Proteins A And D In COPD To Exacerbation Susceptibility, Severity Of Airflow Obstruction And Current Tobacco Smoke Exposure. ATS International Conference, San Francisco, CA. 2012.
  • Biswal S., Harvey C., Thimmulappa R.K., Sethi S, Brown R., Feller-Kopman D.J., Wise R.A.. Enhancing Nrf2 By Sulforaphane Improve Bacterial Phagocytosis By COPD Macrophages And Reduces Bacterial Exacerbations In Cigarette Smoke-Exposed Mice. ATS International Conference, San Francisco, CA. 2012.
  • Houle C., Murray L., Stolar M., Hsieh R., Jones P., Sethi S, Ramachandran S., Goldman M., Leidy N.K.. Reliability And Validity Of EXAcerbations Of Chronic Pulmonary Disease Tool (EXACT) Scores In 3 Clinical Trials. ATS International Conference, San Francisco, CA. 2012.
  • Houle C., Murray L., Stolar M., Hsieh R., Jones P.W., Monz B., Ramachandran S., Goldman M., Sethi S, Leidy N.K.. Quantifying The Severity Of Respiratory Symptoms Of Chronic Obstructive Pulmonary Disease (COPD): Performance Properties Of The EXAcerbations Of Chronic Pulmonary Disease Tool - Respiratory Symptoms (E-RS) In 3 Randomized Controlled Trials. ATS International Conference, San Francisco, CA. 2012.
  • Sethi S, Rennard S.I., Miravitlles M., Martinez F.J., Donohue J.F., Anzueto A., Grossman R., Loutit J., Dudley M.N.. A Phase 2 Study To Evaluate The Safety, Tolerability And Efficacy Of Levofloxacin Inhalation Solution (MP-376) Administered For 5 Days Every 28 Days To Prevent Acute Exacerbations In High Risk COPD Patients. ATS International Conference, San Francisco, CA. 2012.
  • Parameswaran GI, Murphy TF, Yin J., Grove L., Eberhardt E., Berenson CS, Sethi S. Species Specific Susceptibility To Bacterial Colonization And Exacerbation In COPD. ATS International Conference, San Francisco, CA. 2012.
  • Mammen MJ, Qu J, Sethi S. Comprehensive Proteomic Profiling Of Bronchoalveolar Lavage Fluid Of Individuals With COPD Compared To Healthy Controls. ATS International Conference, San Francisco, CA. 2012.
  • Parameswaran GI, Sethi S, Murphy TF. Transcriptional And Cytokine Responses Of Airway Epithelial Cells To Infection In COPD. ATS International Conference, San Francisco, CA. 2012.
  • Sethi S, Wrona C., Eberhardt E., Grove L., Parameswaran GI, Murphy TF. Distinguishing Infecting (New) From Colonizing (Pre-Existing) Nontypeable Haemophilus Influenzae Strains At Exacerbation Of COPD By Molecular And Immunological Assays. ATS International Conference, San Francisco, CA. 2012.
  • Nag N., Bowman S.M., Grove L., Yin J., Sethi S. Static Biofilm Formation Is Not Associated With Longer Duration Of Carriage Of Pseudomonas Aeruginosa Strains In COPD. ATS International Conference, San Francisco, CA. 2012.
  • Provost K, Smith M., Kaushal G., Arold S.P., Hava D.L., Sethi S. Extracellular Calcium During Bacterial Challenge Augments The Innate Immune Response Of Monocyte Derived Macrophages. ATS International Conference, San Francisco, CA. 2012.
  • Jamil M.O., Yin J., Nag N., Eberhardt E., Grove L., Parameswaran GI, Murphy TF, Sethi S. Acquistion Of Pseudomonas Aeruginosa Is Associated With Adverse Clinical Outcomes In COPD. ATS International Conference, San Francisco, CA. 2012.
  • Sethi S, Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., Trajanovic M., Wilson R.. Moxifloxacin (MXF) vs. Amoxicillin/Clavulanic Acid (AMC) In Acute Exacerbations of COPD (AECOPD): Bacteriologic Results of the MAESTRAL Study. ICAAC, Chicago. 2011.
  • Wilson R., Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., Trajanovic M., Sethi S. Moxifloxacin (MXF) vs. amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint. European Respiratory Society Annual Congress, Amsterdam, Netherlands. 2011.
  • Sexton C.C., Leidy N.K., Notte S.M., Jones P., Monz B.U., Nelsen L., Ramachandran S., Sethi S. Quantifying The Severity Of Respiratory Symptoms Of Chronic Obstructive Pulmonary Disease (COPD): Reliability And Validity Of A Patient Diary. ATS International Conference, Denver, CO. 2011.
  • Wilson R., Sethi S, Anzueto A., Miravitlles M., Haverstock D., Trajanovic M., Arvis P.. Maestral (Moxifloxacin In AECB Superiority Trial) Study Protocol: Use Of A Novel 8-Week Post-Therapy Endpoint. ATS International Conference, Denver, CO. 2011.
  • Berim I.G., Lesse AJ, Eberhardt E., Grove L.J., Wrona C., Murphy TF, Sethi S. New Strain Acquisition Of Staphylococcus Aureus In Chronic Obstructive Pulmonary Disease Is Not Associated With Exacerbations. ATS International Conference, Denver, CO. 2011.
  • Desai H.D., Grant B.J.B., Eschberger K., Agrawal A., Murphy TF, Sethi S. Bacterial Colonization Of The Lower Respiratory Tract Increases Daily Symptoms In Patients With Chronic Obstructive Pulmonary Disease. ATS International Conference, Denver, CO. 2011.
  • Huang Y.J., Sethi S, Wrona C., Boushey H,A,, Lynch S.. Airway Bacterial Microbiota Dynamics During COPD Exacerbations. ATS International Conference, Denver, CO. 2011.
  • Sethi S, Berenson CS, Clare R.L., Eberhardt E., Wrona C.. Association Of Impaired Innate Immune Responses Of COPD Alveolar Macrophages With Toll-Like Receptor Polymorphisms. ATS International Conference, Denver, CO. 2011.
  • Parameswaran GI, Sethi S, Murphy TF. Effects Of Bacterial Infection On Airway Antimicrobial Peptides And Proteins In Chronic Obstructive Pulmonary Disease. ATS International Conference, Denver, CO. 2011.
  • Sansgiry S.S., Joish V.N., Boklage S., Goyal R., Seal B., Sethi S. Pseudomonas aeruginosa related economic burden stratified by comorbidity in Cystic Fibrosis patients. International Society for Pharmacoeconomics and Outcomes Research European Congress, Prague, Czech Republic. 2010.
  • Sansgiry S.S., Joish V.N., Boklage S., Goyal R., Seal B., Sethi S. Pseudomonas aeruginosa related burden on Cystic Fibrosis patients: Comparing healthcare costs and resource utilization across age groups.. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress , Prague, Czech Republic. 2010.
  • Sethi S. Impact of Pseudomonas aeruginosa infection on direct medical costs in Cystic Fibrosis.. North American Cystic Fibrosis (NACF) Conference, Baltimore, MD. 2010.
  • Sethi S;Desai H, Eschberger K, Agrawal A, Grant BGB, Murphy TF. Environmental factors and daily symptoms in patients with Chronic Obstructive Pulmonary Disease.. ATS International Conference, New Orleans, LA,. 2010.
  • Sethi S;Eberhardt E, Wrona C, Grove LJ, Clare R, Berenson CS. Bacterial pathogen induction of interleukin-8 (IL-8) and adherence to primary bronchial epithelial cells obtained from patients with COPD.. ATS International Conference, New Orleans, LA. 2010.
  • Sethi S;Desai H, Wrona C, Murphy TF,. Mechanisms of decline in serum bactericidal activity for Nontypeable Haemophilus influenzae (NTHI) in COPD patients chronically colonized with NTHI.. ATS International Conference, New Orleans, LA,. 2010.
  • Sethi S;Jowdy P, Desai H. Proteolysis of Sputum Immunoglobulin A (IgA) in Exacerbations of Chronic Obstructive Pulmonary Disease. Poster Discussion session.. ATS International Conference, New Orleans, LA,. 2010.
  • Sethi S;Harvey CJ, Thimmulappa RK,Yarmus L, Feller-Kopman D, Wise R and S Biswal. Nrf2-dependent immunomodulation by sulforaphane improves bacterial phagocytosis in COPD macrophages and inhibits bacterial burden and inflammation in cigarette smoke-exposed mice.. ATS International Conference, New Orleans, LA. 2010.
  • Sethi S;Leidy NK, Wilcox TK,P.W. Jones.. How Stable Is Stable in COPD? An Analysis of Day-to-Day EXACT Score Variability in Acute and Stable Patients with COPD.. ATS International Conference, San Diego, CA,. 2009.
  • Sethi S;Jung J, Thomas MK, Sethi R ,Tewke CD, Murphy TF. New Strain Acquisition of Klebsiella Spp, Enterobacter Spp and Escherichia coli in COPD Is Not Associated with Exacerbations.. ATS International Conference, San Diego, CA. 2009.
  • Sethi S;El-Dika N, Wrona C, Eschberger K and TF Murphy. Molecular Methods Detect Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis in Sputum in COPD with Much Higher Frequency Than Culture Methods.. ATS International Conference, San Diego, CA,. 2009.
  • Sethi S, Parameswaran, G.I., Murphy TF. Antimicrobial Polypeptides and Moraxella Catarrhalis in COPD.. ATS International Conference, San Diego, CA. 2009.
  • Sethi S;Rupp A, Romberger DJ, Tang L,T.D. LeVan.. Differential Susceptibility of Nontypeable Haemophilus influenzae Strains to the Antimicrobial Peptide, Human ß-Defensin-2, in COPD Subjects.. ATS International Conference, San Diego, CA. 2009.
  • Sethi S;Sigua N, Rajashekhar G, Fehrenbach H, Kamocki K, Adamowicz J, Garrison J, Rush NI, Voswinckel R, Twigg III HL,Clauss M, I. Petrache.. EMAP II Is a Novel Cigarette Smoke-Induced Biomarker in Emphysema.. ATS International Conference, San Diego, CA. 2009.
  • Sethi S;Wrona C, Grove L, Palaniyar N,CS Berenson. Antimicrobial Polypeptides in Bronchial Lavage and Bronchoalveolar Lavage: Effects of COPD and Current Smoking. Oral presentation, Mini-Symposium, Innate lung defense in chronic obstructive pulmonary disease.. ATS International Conference, San Diego, CA,. 2009.
  • Sethi S;Berenson CS, Clare RL, Maloney J,. Distinct Innate Immune Responses of COPD Alveolar Macrophages to Different Respiratory Bacterial Pathogens. Oral presentation, Mini-Symposium, Innate lung defense in chronic obstructive pulmonary disease.. ATS International Conference, San Diego, CA,. 2009.
  • Sethi S;Siddiqi A, Berim I, Nabi H, Berenson CS. Association of Impaired Mucociliary Clearance with Occurrence of Exacerbations in COPD. Oral presentation, Mini-Symposium, Chronic obstructive pulmonary. . ATS International Conference, San Diego, CA. 2009.
  • Sethi S;Wilcox T, Leidy NK, PW Jones. Patterns of Recovery from Exacerbations of COPD: EXACT Change Scores Days 1–14. Oral presentation, Mini-Symposium, Chronic obstructive pulmonary disease exacerbation: mechanism and management.. ATS International Conference, San Diego, CA,. 2009.
  • Sethi S;Parameswaran GI,TF Murphy. Protease-Antiprotease Balance Is Altered in Colonization and Exacerbation Due to Moraxella Catarrhalis in COPD.. ATS International Conference, San Diego, CA,. 2009.
  • Sethi S;Siddiqi A, Grove L, Lobbins P, Eschberger K, Murphy TF,. Comparison of Antibiotic Susceptibility of Pseudomonas aeruginosa Strains Isolated from Sputum in COPD with Nosocomial Strains.. ATS International Conference, Toronto, Canada. 2008.
  • Sethi S;Wilcox TK, Leidy NK, Chen WH,Jones PW.. Does a Measurement Tool of COPD Exacerbation Have a Single Measurement Scale with Multiple Domains? Exploratory and Confirmatory Factor Analysis of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT).. ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S;Leidy NK, Wilcox TK, Burke LB, Howard KA, Petrillo JM, Jones PW,Powers JH.. Reliability and Validity of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT): A New Outcome Measure for Evaluating Exacerbations in COPD.. ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S and the PULSE study group. Determinants of Exacerbation Frequency in the PULSE Study.. ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S;Jones PW, Chen WH, Leidy NK, Petrillo JM,. Creating a Unidimensional Measure of Overall Exacerbation Severity: The Exacerbations of Chronic Pulmonary Disease Tool (EXACT).. ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S;Wrona C, Eschberger K, Lobbins P, TF Murphy.. Airway Inflammation and Acquisition of New Strains of Moraxella catarrhalis in COPD.. ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S. Development of a Patient-Reported Outcome (PRO) Measure in AECOPD.. ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S;Wrona C, Grove L, Maloney J, C. Berenson.. Bronchial Lysozyme, Lactoferrin and SLPI Concentrations in Ex-Smokers with and without COPD.. . ATS International Conference, Toronto, Canada. 2008.
  • Sethi S;Richardson SK, Manzel LJ, Murphy TF, St. Geme III JW, DC Look. Cigarette Smoke Extract Alters Bacterial Adherence of Nontypeable Haemophilus influenzae to Airway Epithelial Cells.. .ATS International Conference, Toronto, Canada,. 2008.
  • Sethi S;Wrona C, Grove L, Maloney J, Berenson C, N. Palaniyar. Bronchoalveolar Lavage Levels of Surfactant Protein A and D Levels Are Decreased in Ex-Smokers with COPD.. ATS International Conference, Toronto, Canada. 2008.
  • Sethi S; Siddiqi A, Wrona C, Eschberger K, Murphy TF,. Serum C-Reactive Protein (CRP) in COPD and Its Relationship to Inhaled and Systemic Corticosteroid Use.. ATS International Conference, Toronto, Canada. 2008.
  • Sethi S;Lucht LA, Kristoff J, Norris KA,Sciurba FC, Wei K, Tseng W, A. Morris.. Pneumocystis Antibody Response and Colonization in COPD.. ATS International Conference, Toronto, Canada. 2008.
  • Sethi S and the PULSE study group. Reduction in Number of Acute Exacerbations of COPD with Moxifloxacin in Patients with Mucopurulent/Purulent Sputum: A PULSE Study Sub-Analysis. Oral presentation.. ATS International Conference, Toronto, Canada. 2008.
  • Sethi S;Van Parijs BA,Lode H, Wilson R, Bhatt K, Fernandes A, Berkowitz E, Chang C, Nicholson T, Li G, Jones PW. Patient-Reported Outcome (PRO) Measure in AECOPD.. ICAAC, Chicago, IL,. 2007.
  • Sethi S. Clinical and safety results of the PULSE Study. Oral presentation.. ERS Annual Congress, Stockholm, Sweden,. 2007.
  • Sethi S;Kruesmann F, Haverstock D, Perroncel R, Choudhri SH.. Correlation between eradication of infecting organism on days 3 to 5 of antibiotic therapy and clinical cure in patients with acute exacerbations of chronic bronchitis (AECB).. ERS Annual Congress, Stockholm, Sweden. 2007.
  • Sethi S;Gaillat J, Garau J,Anzueto A, Guillemot D, Weber P.. Impact of telithromycin, azithromycin and cefuroxime axetil on the carriage of resistant Streptococcus pneumoniae in patients with acute exacerbation of chronic bronchitis.. ERS Annual Congress, Stockholm, Sweden,. 2007.
  • Sethi S;Leidy NK, Howard K, Petrillo J, Wilcox T,Jones PW,. EXACT-PRO Study Group. The EXAcerbation of Chronic Pulmonary Disease Tool [EXACT]: A Patient-Reported Outcome.. ATS International Conference, San Francisco, CA,. 2007.
  • Sethi S;Richardson SK, Cholon DM, Chin CL, Murphy TF, Sethi S, St. Geme III JW, Look DC.. Altered Adhesin Expression on Persistent Haemophilus influenzae Strains from Patients with Chronic Obstructive Pulmonary Disease.. ATS International Conference, San Francisco, CA,. 2007.
  • Sethi S;Wrona C, Cai X,Eschberger K, Murphy TF. Stability of Serum C-Reactive Protein (CRP) in COPD and Its Relationship to Exacerbation Frequency and Mortality.. ATS International Conference, San Francisco, CA. 2007.
  • Sethi S;Veeramachaneni S, Murphy TF, Wrona C, Eschberger K. Serum IgG and Sputum IgA Antibody Levels to Nontypeable Haemophilus influenzae Are Markers of Recurrent Infection in COPD.. ATS International Conference, San Francisco, CA. 2007.
  • Sethi S;Clare RL, Grove L, Maloney J, Berenson CS. Complement Mediation of Human Alveolar Macrophage Phagocytosis Is Distinct for Different Respiratory Pathogens.. ATS International Conference, San Francisco, CA,. 2007.
  • Sethi S;Wrona C, Murphy TF.. Identification of Nontypeable Haemophilus influenzae (NTHI) Antigens for Human Bactericidal Antibodies That Develop Following Acute Exacerbations of COPD.. ATS International Conference, San Francisco, CA. 2007.
  • Sethi S;El-Dika N, T.F. Murphy TF, Wrona C, Eschberger K,. PCR Detection of Streptococcus pneumoniae and Moraxella catarrhalis in Sputum in the Stable Phase and during Exacerbations of COPD.. ATS International Conference, San Francisco, CA. 2007.
  • Sethi S. Intermittent Pulse Therapy of Moxifloxacin To Prevent Acute Exacerbations in COPD Patients with Chronic Bronchitis: Demographics and Baseline Bacteriology.. ATS International Conference, San Francisco, CA. 2007.
  • Sethi S. An epidemiological analysis of Streptococcus pneumoniae infection in outpatient acute exacerbations of chronic bronchitis (AECB).. ECCMID/ICC, Munich, Germany,. 2007.
  • Sethi S;Anzueto A, Wilson R, Jones PW, Wedzicha JA, Miravitlles M, Kureshi A, Sagnier P, Russell J, Schmitt M, Arvis P, Hampel B.. Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data.. ERS Annual Congress, Munich, Germany. 2006.
  • Sethi S;Murphy TF, Cai X, Richter SS, Doern GV. Antibiotic exposure in COPD and the development of penicillin and erythromycin resistance in Streptococcus pneumonia.. ICAAC, San Francisco, CA,. 2006.
  • Sethi S;Brauer AL, Lesse AJ,Kilian M, Cai X, Murphy TF. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. (Abstract). American Society for Microbiology 106th General Meeting. Orlando, FL,. 2006.
  • Sethi S;Grove L, Wrona C, Maloney J.. Prevalence of bacterial colonization in COPD is not altered by fluticasone/salmeterol.. ATS International Conference, San Diego, CA,. 2006.
  • Sethi S;Wei KK,Tseng W, Morris A.. Detection of Pneumocystis in subjects with COPD exacerbations.. ATS International Conference, San Diego, CA,. 2006.
  • Sethi S;Wrona C, Veeramachaneni S, Eschberger K, Murphy TF. Changes in serum c-reactive protein (CRP) with onset and resolution of exacerbations of COPD and relationship to etiology.. ATS International Conference, San Diego, CA,. 2006.
  • Sethi S;Veeramachaneni S, Wrona C, Murphy TF,. Lack of host immune and inflammatory response to gram-negative bacilli in exacerbations of COPD.. ATS International Conference, San Diego, CA. 2006.
  • Sethi S;ElDika N, Eschberger K, Lobbins P, Murphy TF,. Relationship of Pseudomonas aeruginosa isolation to lung function, hospitalization and mortality in COPD.. ATS International Conference, San Diego, CA,. 2006.
  • Sethi S;Fernaays MM, Lesse AJ, Murphy TF. Genes Associated with Virulence of Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.. American Society of Microbiology Annual Meeting, Atlanta, GA,. 2005.
  • Sethi S;. Identification of Surface Antigens of Moraxella catarrhalis as Targets of Human Serum Antibody Responses in Chronic Obstructive Pulmonary Disease.. .American Society of Microbiology Annual Meeting, Atlanta, GA. 2005.
  • Sethi S;Johnson A, Kazani S, Hiltke TJ,. Musher DM, Ceasar H, Hollingshead SK, Coan PA, Briles DE, Morona J, Paton JC,Murphy TF.. Antibody Response to Capsular and Noncapsular Antigens of Streptococcus pneumoniae in Chronic Obstructive Pulmonary Disease.. American Society of Microbiology Annual Meeting, Atlanta, GA,. 2005.
  • Sethi S;Delgado EM, Eschberger K, Lobbins P, Murphy TF. Acquisition of New Bacterial Strains in COPD Is Independent of Systemic Antibiotic and Corticosteroid Use.. ATS International Conference, San Diego, CA,. 2005.
  • Sethi S;Eschberger K, Lobbins P, Sethi R, Agarwal S, Grant BJB, Murphy TF. Sputum Bacterial Titers and Acute Exacerbations of COPD.. ATS International Conference, San Diego, CA. 2005.
  • Sethi S;Wrona C Eschberger K, Lobbins P, Murphy TF. Changes in Airway Inflammation with Onset and Resolution of Exacerbations of COPD.. ATS International Conference, San Diego, CA. 2005.
  • Sethi S;Maloney J, Grove L, Wrona C, Berenson C.. Inflammatory Cytokine Response of Alveolar Macrophages to Outer Membrane Components of Nontypeable Haemophilus influenzae (NTHI) Is Diminished in COPD.. ATS International Conference, San Diego, CA. 2005.
  • Sethi S;Garlipp MA, Maloney J, Berenson C.. Phagocytosis of Nontypeable Haemophilus influenzae (NTHI) by Alveolar Macrophages Is Diminished in COPD.. ATS International Conference, San Diego, CA,. 2005.
  • Sethi S;Brown S, Patel M.. Antibacterial Activity of Telithromycin and Comparators Against Pathogens Isolated from Patients with Acute Exacerbations of Chronic Bronchitis in PROTEKT (1999–2003).. ATS International Conference, San Diego, CA. 2005.
  • Sethi S;Brauer A Lesse AJ, Doern GV, Murphy TF. Distinct Clinical Characteristics of Variant Strains of Nontypeable Haemophilus influenzae (NTHI) Isolated from Patients with COPD.. .ATS International Conference, San Diego, CA. 2005.
  • Sethi S;Morris A, Sciurba FC, Tseng W, Norris KA,. Relationship of Pneumocystis Colonization and COPD.. ATS International Conference, San Diego, CA. 2005.
  • Sethi S;Wrona C, Maloney J, Berenson C. Bacterial Colonization Is Associated with Increased Matrix Metalloproteinase-9 (MMP-9) in Bronchoalveolar Lavage of Ex-Smokers with Stable COPD.. ATS International Conference, San Diego, CA,. 2005.
  • Sethi S;Johnson AJ, Kazani S, Hiltke T, Sethi S, Ceaser H, Musher D, Murphy TF. Human antibody response to Streptococcus pneumoniae in chronic obstructive pulmonary disease.. American Society of Microbiology Annual Meeting, New Orleans, LA. 2004.
  • Sethi S;Brauer A, Lobbins P, Eschberger K, Murpy TF. Systemic and mucosal immune response to Moraxella catarrhalis in COPD.. ATS International Conference, Orlando, FL. 2004; A84.
  • Sethi S. Serum immune response to ‘colonization’ by Haemophilus influenzae in COPD.. ATS International Conference, Orlando, FL,. 2004; D84.
  • Sethi S;Maloney J, Grove L, Wrona C, Berenson CS.. Bacterial ‘Colonization’ of the Lower Respiratory Tract Is Associated with Airway Inflammation in Ex-Smokers with Stable COPD.. ATS International Conference, Orlando, FL,. 2004.
  • Sethi S;Berenson C, Wrona C, Grove L, Maloney J. Nontypeable Haemophilus influenzae antigen regulation of human macrophage inflammation.. American Society of Microbiology Annual Meeting, New Orleans, LA,. 2004.
  • Sethi S;Garlipp M, Sethi S, Grove L, Maloney J, Berenson C.. Phagocytosis and intracellular survival of Nontypeable Haemophilus influenzae in human alveolar macrophages in chronic obstructive pulmonary disease.. American Society of Microbiology Annual Meeting, New Orleans, LA,. 2004.
  • Sethi S. Serum immune response to ‘colonization’ by Haemophilus influenzae in COPD.. American Society of Microbiology Annual Meeting, New Orleans, LA. 2004.
  • Sethi S;Grove L, Murphy TF,. Epithelial cell invasion and phosphorylcholine expression among complement sensitive and resistant strains of Haemophilus influenzae isolated from patients with exacerbations of COPD.. American Society of Microbiology Annual Meeting, New Orleans, LA. 2004.
  • Sethi S;Wrona C, Braciak C, Freeburg R, Evans N, Murphy TF. Strain specific immune response to Haemophilus influenzae in exacerbations of COPD.. ATS International Conference, Seattle, WA. 2003; A16.
  • Sethi S;Maloney J, Grove L, Smigiera J, Berenson C.. Colonization’ of the lower respiratory tract and airway neutrophilia in ex-smokers with stable COPD.. ATS International Conference, Seattle, WA. 2003; A32.
  • Sethi S;, Maloney J, Grove L, Wrona C, Hawkins S. Safety and efficacy of sputum induction with the lung flute in healthy subjects.. ATS International Conference, Seattle, WA,. 2003; B49.
  • Sethi S;Maloney J, Grove L, Wrona C, Hawkins S.. Comparison of the safety and efficacy of sputum induction with the lung flute and with hypertonic saline in COPD.. ATS International Conference, Seattle, WA,. 2003; B49.
  • Sethi S;Veeramachaneni S, Murphy TF. Serum immune response to Pseudomonas aeruginosa, other gram-negative bacilli and Haemophilus parainfluenzae in acute exacerbations of COPD.. ATS International Conference, Seattle, WA,. 2003; D92.
  • Sethi S. Strain specific immune response to Haemophilus influenzae in exacerbations of COPD.. . American Society of Microbiology Annual Meeting, Washington, DC,. 2003.
  • Sethi S;Brauer AL, Sethi S, Murphy TF.. New serum IgG and sputum IgA to Moraxella catarrhalis following exacerbations and asymptomatic colonization of adults with chronic obstructive pulmonary disease.. American Society of Microbiology Annual Meeting, Washington, DC,. 2003.
  • Sethi S;Berenson C, Smigiera J, Grove L, Wrona C,. Nontypeable Haemophilus influenzae antigen regulation of human macrophage inflammation.. American Society of Microbiology Annual Meeting, Washington, DC,. 2003.
  • Sethi S;Obaji A, Murphy TF,. Relationship of sputum elastase to clinical and bacteriological states in COPD.. ATS International Conference, Atlanta, GA,. 2002; B28.
  • Sethi S;Ahn JH, Wrona C,. Exacerbation and transient colonization strains of nontypeable Haemophilus influenzae differ in invasion and pro-inflammatory cytokine induction of H292 cells.. ATS International Conference, Atlanta, GA. 2002; B37.
  • Sethi S;Hiltke TJ, Schiffmacher AT, Murphy TF.. Horizontal transfer of the gene encoding outer membrane protein 2 in a patient with chronic obstructive pulmonary disease.. American Society of Microbiology Annual Meeting, Salt Lake City UT,. 2002.
  • Sethi S;Brauer AL, Murphy TF.. Strain specificity and duration of human immune response to Moraxella catarrhalis.. American Society of Microbiology Annual Meeting, Salt Lake City UT. 2002.
  • Sethi S;Evans N, Murphy TF. Acquisition of a new bacterial strain and occurrence of exacerbation of COPD.. ATS International Conference, Atlanta, GA,. 2002; B28.
  • Sethi S;Evans N, Wrona C, Walters A, Murphy TF. Human immune response to ‘colonization’ by Haemophilus influenzae in stable COPD.. ATS International Conference, San Francisco, CA,. 2001; B30.
  • Sethi S;Veeramachaneni S, Evans N, Wrona C, Walters A, Murphy TF. Human immune response to Haemophilus spp. in acute exacerbations of COPD.. ATS International Conference, San Francisco, CA,. 2001; C92.
  • Sethi S;Obaji A, Murphy TF. Lung function decline in advanced COPD.. ATS International Conference, San Francisco, CA. 2001; C52.
  • Sethi S;Walters A, Veeramachaneni S, Murphy TF.. Characterization of bactericidal antibodies to tbp2 (OMP B1) of M. catarrhalis.. American Society of Microbiology Annual Meeting, Orlando Fl,. 2001; B337.
  • Sethi S;Hiltke TJ, Murphy TF.. Sequence stability of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae in the human respiratory tract.. American Society of Microbiology Annual Meeting, Orlando Fl,. 2001; B246.
  • Sethi S;Bakri FG, Murphy TF. Human immune response to Moraxella catarrhalis following exacerbations of chronic obstructive pulmonary disease.. American Society of Microbiology Annual Meeting, Orlando Fl,. 2001; E7.
  • Sethi S;Veeramachaneni S, Evans N, Wrona C, Grant BJB.. Airway inflammation in stable COPD: effect of bacterial colonization is independent of smoking and severity of airway obstruction.. ALA/ATS International Conference, Toronto, Ontario, May 2000.. 2000; D32.
  • Sethi S;Evans N, Wrona C, Murphy TF. Airway inflammation in COPD: effects of clinical status and bacterial infection.. ALA/ATS International Conference, Toronto, Ontario,. 2000; D32.
  • Sethi S;Wrona C, Murphy TF.. Characterization of adherence of Moraxella catarrhalis to Hep-2 cells.. American Society of Microbiology Annual Meeting, Los Angeles CA. 2000; B121.
  • Sethi S;Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF.. Comparison of airway inflammation in acute bacterial and non-bacterial exacerbations of COPD.. ALA/ATS International Conference, San Diego CA. 1999; D31.
  • Sethi S;Yuskiw N, Klingman KL, Brueggemann AB, Doern GV, Murphy TF. Simultaneous respiratory tract colonization by multiple strains of nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease: implications for antibiotic therapy.. American Society of Microbiology Annual Meeting, Chicago IL,. 1999; A57.
  • Sethi S;Paluri R, Murphy TF. Sputum bacterial titers do not increase during acute exacerbations of chronic obstructive pulmonary disease (COPD).. American Society of Microbiology Annual Meeting, Chicago IL,. 1999; D/B(289).
  • Sethi S;Muscarella K, Evans N, Klingman KL, Grant BJB, Murphy TF. Bacterial colonization enhances airway inflammation.. ALA/ATS International Conference, San Diego CA. 1999; D31.
  • Sethi S;Paluri R, Grant BJB, Murphy TF. Prediction models for the etiology of acute exacerbations of COPD.. ALA/ATS International Conference, San Diego ,CA. 1999; D31.
  • Sethi S;Ameen KA, Murphy TF. Mapping of monoclonal antibodies 1F5 and 2.9F to the first variable region of CopB (OMP B2) of Moraxella (Branhamella) catarrhalis.. American Society of Microbiology Annual Meeting, Atlanta GA. 1998; B359.
  • Sethi S;Wrona CT, Klingman KL, Murphy TF.. Serum opsonic antibody response to Moraxella (Branhamella) catarrhalis in acute exacerbations of chronic obstructive pulmonary disease (COPD).. American Society of Microbiology Annual Meeting, Atlanta GA. 1998; B360.
  • Sethi S;Pingle D, Klingman KL, Murphy TF.. Detection of Haemophilus DNA from culture negative sputa in COPD.. American Thoracic Society General Meeting, Chicago IL. 1998; A58.
  • Sethi S;Ameen K, Murphy TF, Klingman KL,. Immune response to M. catarrhalis in COPD exacerbations.. . American Thoracic Society General Meeting, San Francisco CA, May. 1997; A37.
  • Sethi S;Muscarella KA, Murphy TF. Serum bactericidal activity for nontypeable Haemophilus influenzae (NTHI): the third factor phenomenon.. American Society of Microbiology Annual Meeting, Miami Beach FL. 1997; E34.
  • Sethi S;Kirkham C, Murphy TF. Human immune response to outer membrane protein E of Branhamella catarrhalis.. American Society of Microbiology Annual Meeting, Miami Beach FL. 1997; B7.
  • Sethi S;Klingman K, Evans N, Muscarella K, Murphy TF.. Exacerbations of COPD are associated with acquisition of new strains of bacterial pathogens.. American Thoracic Society General Meeting, New Orleans LA. 1996; D39.
  • Sethi S;Murphy E, Muscarella KA, Murphy TF. Dynamics of respiratory tract colonization by nontypeable Haemophilus influenzae in patients with COPD.. American Society of Microbiology Annual Meeting, New Orleans, LA. 1996; B178.
  • Sethi S;Evans N, Muscarella K, Klingman K, Murphy TF.. Sputum induction in stable chronic obstructive pulmonary disease (COPD): effect on sputum bacteriology.. American Thoracic Society General Meeting, Seattle WA. 1995; D76.
  • Sethi S;Murphy TF. Molecular analysis of the outer membrane protein (OMP) B2 gene of Moraxella (Branhamella) catarrhalis.. American Society of Microbiology Annual Meeting, Washington D.C.. 1995; B156.
  • Sethi S;Murphy TF, Hill SL.. Serum antibody response to Moraxella catarrhalis in bronchiectasis.. American Thoracic Society General Meeting, Boston MA. 1994; A31.
  • Sethi S;Surface JM, Sethi S, DeNardin E, Murphy TF. Antigenic heterogeneity of outer membrane protein B of Moraxella (Branhamella) catarrhalis.. American Society of Microbiology Annual Meeting, Las Vegas NV. 1994; D223.
See all (146 more)
Evaluative Studies and Case Reports:
  • Kamen Rangelov, Sethi S. The First Described Case of Occupational Anthracofibrosis in the USA. Case Reports in Pulmonology. 2014; 2014(46059).
  • Sethi S, W Sequiera. Sparing effect of hemiplegia on scleroderma.. Annals of Rheumatic Diseases. 1990; 49.

Professional Memberships:
  • ACP; Fellow (2009–present)
  • American Thoracic Society (1990–present)
Presentations:
  • "Changing Paradigms in the Prevention of COPD Exacerbations." Grand Rounds, Quinnipiac Frank H. Netter School of Medicine, Quinnipiac University (2017)
  • "COPD Phenotypes, Outside Looking In" Yale State Chest Conference, Yale School of Medicine (2017)
  • "Lung Microbiome in COPD: Progress and Pitfalls" Yale School of Medicine Research Conference, Yale School of Medicine, Pulmonary Division (2017)
  • "How Should I Treat a Patient Who Has an Acute Worsening in Symptoms?" ATS International Conference, American Thoracic Society, Post Graduate Course PG19 (2016)
  • "Bacterial Infection in COPD: Consequences and Mechanisms" Irish Thoracic Society Annual Meeting (2015)
  • "Severe Infections in COPD. Session 5: Severe infections in COPD and cystic fibrosis." LUSEP: The first Lund conference on severe infections and sepsis. (2015)
  • "Microbiology in Bronchiectasis: Emerging Tools to Identify Pathogens. The frontiers of bronchiectasis." ATS International Conference, ATS (2015)
  • "The Frequent Exacerbator: Determining the Biological Basis. Preventing COPD exacerbations: moving towards targeted and personalized treatment." ATS International Conference, ATS (2015)
  • "The Microbiome in COPD." ATS International Conference, ATS (2015)
  • "The role of the lung microbiome in COPD pathogenesis." Heart & Lung Scientific Symposium, University of British Columbia, Graeme Copland Memorial Lecture (2015)
  • "COPD Exacerbations: An Update." Chest 2014, Chest, Panel Discussion (2014)
  • "Host defense: ABCD." PULMOCON, Symposium: Lung Infections: Review of the basic issues. (2014)
  • "Infection in the pathogenesis of COPD." PULMOCON (2014)
  • "LRTI: COPD exacerbation" PULMOCON (2014)
  • "Reducing Relapse Rates for Cigarette Smoking and AECOPD" Chest 2014, Chest, Small Case-Based Interactive Discussion. (2014)
  • "Strategies to Reduce Readmissions for COPD." Chest 2014, Chest, Morning Educational Symposium: AECOPD: Strategies to Improve Outcomes and Reduce Readmission Rates. (2014)
  • "Treatment of infection in COPD exacerbations" European Respiratory Society Annual Congress, Postgraduate Course: Lower respiratory tract infections: learning from real clinical cases (2014)
  • "Infection in exacerbations of COPD: More than meets the eye." 28th Annual Doctor Dorothy Wiselberg Seminar, McGill University Health Centre Division of Respiratory Medicine, Emerging Respiratory Infections (2014)
  • "Macrolides to Prevent Exacerbations in Chronic Obstructive Pulmonary Disease: Ready for Prime Time?" ATS International Conference, ATS, Symposium: Macrolides in respiratory infections: panacea or pandora's box? (2014)
  • "New Concepts in COPD Exacerbations" ATS International Conference, ATS, Postgraduate Course: COPD: Progress and Controversies (2014)
  • "Preventing COPD exacerbations: Why and How?" International Conference on Insights and Management of COPD (ICONIC) (2014)
  • "Selecting an antibiotic: an art and the science." PULMOCON, Symposium: International symposium on LRTI (2014)
  • "Haemophilus influenzae in COPD" Pittsburgh Lung Conference (2013)
  • "ICU Management of COPD. Symposium: Pathogenesis & Management of COPD" Second update on Asthma & COPD (2013)
  • "Use of antibiotics in asthma and COPD" Second update on Asthma & COPD, Symposium: Asthma and COPD: Similarities and Differences (2013)
  • "Treating Exacerbations-Prednisone, antibiotics, or both? Symposium: Opportunities to Advance the Care of COPD Exacerbations." COPD8 USA Conference, The COPD Foundation (2013)
  • "What Do We Know About Exacerbations? Symposium: The Science of Exacerbations." COPD8 USA Conference, The COPD Foundation (2013)
  • "Chronic obstructive lung disease: can biomarkers discriminate between causes of acute exacerbations and pneumonia." ATS International Conference, ATS, Postgraduate course: Clinical applications of novel diagnostics and biomarkers for management of respiratory and critical illness. (2013)
  • "Current knowledge of bacterial exacerbations. Symposium: Exacerbations of chronic obstructive pulmonary disease: current state of knowledge." ATS International Conference, ATS (2013)
  • "How to deal with the frequent exacerbator? Symposium: Case based learning in Chronic Obstructive Pulmonary Disease management." ATS International Conference, American Thoracic Society (2013)
  • "Long term antibiotic and macrolide therapy in COPD." ATS International Conference, ATS, Postgraduate course: Update in Chronic obstructive pulmonary disease management/ (2013)
  • "ICU management of acute exacerbation of COPD" KEEP Program in Respiratory Diseases, Wave Two, COPD, Sleep Apnea and Lung infection (2012)
  • "Management of community acquired pneumonia" KEEP Program in Respiratory diseases, Wave Two, COPD, Sleep Apnea and Lung Infection (2012)
  • "Practical consideration in managing lung infection. KEEP Program in Respiratory diseases, Wave Two" KEEP Program in Respiratory diseases, Wave Two, COPD, Sleep Apnea and Lung infection (2012)
  • "Ventilator associated pneumonia" KEEP Program in Respiratory diseases, Wave Two, COPD, Sleep Apnea and Lung infection (2012)
  • "How can we better prevent exacerbations of COPD? Symposium : Prevention and treatment of infective exacerbations of COPD." European Respiratory Society Annual Congress, European Respiratory Society, Symposium : Prevention and treatment of infective exacerbations of COPD. (2012)
  • "Infection and inflammation in AECOPD: understanding patient phenotypes." European Respiratory Society Annual Congress, European Respiratory Society Annual Congress, Evening Symposium : Prevention of exacerbations in COPD: expanding scope and strategies. (2012)
  • "Altered innate lung defense: the biological basis of exacerbation susceptibility?" ATS International Conference, ATS, ? Postgraduate Course: Exacerbations of chronic obstructive pulmonary disease: measurement, mechanisms, modeling and management. (2012)
  • "Bacterial infection and mucus hypersecretion" ATS International Conference, ATS, Symposium: Mechanisms and implications of mucus accumulation in chronic obstructive pulmonary disease. (2012)
  • "Pharmacological treatment of stable copd: when and with what?" ATS International Conference, ATS, Thematic Seminar Series: Chronic obstructive pulmonary disease. (2012)
  • "Pneumonia: Newer Pathogens, New Resisitance." Internal Medicine 2012 American College of Physicians Annual Conference., American College of Physicians (2012)
  • "An Exacerbation Free COPD Patient: Is that a Pipe Dream" Yale State Chest Conference, Yale University (2012)
  • "Antibiotic treatment of exacerbations of COPD: when, why and how" European Respiratory Society Annual Congress, European Respiratory Society, Meet the Professor Seminar (2011)
  • "Bacteria in acute exacerbations of COPD: Cause or co-morbidity?" European Respiratory Society Annual Congress, European Respiratory Society, Evening Symposium: New decade, new approaches to respiratory tract infections. (2011)
  • "Chosing the right antimicrobial, route of administration and dosage for chronic bronchial infection." European Respiratory Society Annual Congress, European Respiratory Society, Symposium: Chronic Bacterial infection: more than a syndrome (2011)
  • "Mechanisms of Bacterial Infection in COPD. Mini-symposium: COPD exacerbations: impact of bacterial and viral infections" ATS International Conference, American Thoracic Society (2011)
  • "Controversies in the management of adult respiratory infections: What is the role of combination therapy in severe CAP and VAP?" Lebanese Pulmonary Society Annual Congress,, Lebanese Pulmonary Society (2011)
  • "Prior Antibiotic Use: Why does it Matter in Community Acquired Pneumonia (CAP)?" Lebanese Pulmonary Society Annual Congress, Lebanese Pulmonary Society (2011)
  • "Bacterial Infection in COPD, Consequences and Mechanisms." Pulmonary Grand Rounds, University of Massachusetts (2011)
  • "Treating for better outcomes: the role of moxifloxacin in AECB" Asia Pacific Society of Respirology Annual Congress, Asia Pacific Society of Respirology, Satellite Symposium (2010)
  • "Acute Exacerbations of Chronic Bronchitis (AECB). Who Needs Antibiotics?" European Respiratory Society Annual Congress, European Respiratory Society, Evening symposium (2010)
  • "The Evidence for Long-Term Antimicrobials in Reducing Exacerbations of COPD." European Respiratory Society Annual Congress, European Respiratory Society, evening symposium (2010)
  • "Infection In COPD: Pathogenesis And Treatment." Meet the Professor Seminar, ATS International Conference (2010)
  • "Exacerbations of COPD, More than Chest Colds." Pulmonary Grand Rounds, Cedars Sinai Hospital (2010)
  • "Bacterial Infection in COPD, Consequences and Mechanisms." Research Grand Rounds, Lovelace Respiratory Research Institute, (2010)
  • "Bacterial Infection in COPD, Consequences and Mechanisms" Pulmonary Grand Rounds, University of Iowa (2010)
  • "Exacerbations of COPD. Symposium: Exacerbations of Chronic respiratory Disease: State of the Art" CHEST (2009)
  • "Update in the Current Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD)." Independent Health Foundation (2009)
  • "Exacerbations of COPD: Mechanisms, Management and Prevention." Chicago Thoracic Society (2009)
  • "Etiology of COPD Exacerbations: The Microbiological Link." CHEST, Panel Discussion. Revisitng COPD exacerbations. (2008)
  • "Bacterial infection in COPD:" European Respiratory Society Research Seminar: (2008)
  • "Infection And COPD Exacerbation: What Is The Evidence? Symposium: COPD exacerbations: Epidemiology, prevention and treatment." American Thoracic Society International Conference, (2008)
  • "Measuring The “Exacerbation”. Symposium: Measuring outcome in COPD: How do we move the field?" American Thoracic Society International Conference (2008)
  • "Pulmonary Infections In The Immunocompetent Host. Symposium: Clinical year in review 2." American Thoracic Society International Conference (2008)
  • "PULSE: Impact Of Antibiotic Prophylaxis Symposium: Changing the natural history of COPD: Results of major clinical trials." . American Thoracic Society International Conference (2008)
  • "Acute exacerbations of chronic bronchitis (AECB) clinical trial design: relevant end-points. Evening symposium" European Respiratory Society Annual Congress (2007)
  • "Patient’s experience of symptoms during COPD exacerbations. Evening symposium" European Respiratory Society Annual Congress (2007)
  • "Role of Infection in Disease Pathogenesis. Postgraduate Course Session: COPD: State of the art for the clinician and Researcher." American Thoracic Society International Conference (2007)
  • "Causes of Acute Exacerbations. Plenary Session: Exacerbations." Clinical Consensus on COPD (2007)
  • "Patient reported outcomes in AECB. Plenary Session." Fourth Forum on Respiratory Tract Infections (2007)
  • "Taking a closer look at the AECB patient. Evening Symposium: Not all patients are the same – optimizing outcome in respiratory tract infections." European Respiratory Society Annual Congress (2006)
  • "Importance of antimicrobial therapy. Symposium: Exacerbations." COPD 5 (2006)
  • "Adding oil to the fire: systemic and mucosal inflammation in exacerbations. Symposium: Is COPD an inflammatory disease." American Thoracic Society International Conference (2006)
  • "Bacterial microbes and COPD: Cause or effect." American Thoracic Society International Conference, Postgraduate Course Session: What’s new in COPD: Fourth leading cause of death in the 21st century. (2006)
  • "Current concepts and future trends in the diagnosis and treatment of RTI’s. Symposium: Advances in respiratory infection treatment." 9th Annual Making a Difference in Infectious Disease (MAD-ID) Pharmacotherapy Conference (2006)
  • "Role of Infection in Disease Pathogenesis" American Thoracic Society International Conference, Postgraduate Course Session: COPD: Update for the Clinician and Researcher (2006)
  • "The role of Haemophilus influenzae in COPD. Symposium: Molecular and epidemiologic tools to study respiratory infections: Recent advances, current controversies and future directions" American Thoracic Society International Conference (2006)
  • "COPD: What therapy works?" American College of Physicians Annual Conference (2006)
  • "Mechanisms of colonization and effects of exacerbations. Symposium: COPD progression – from smoking to Chronic Respiratory Failure." 5th International Conference on Management and Rehabilitation of Chronic Respiratory Failure. (2006)
  • "Acute exacerbations of COPD, What is new?" Yale State Chest Conference (2005)
  • "Pathogenesis of acute exacerbations of chronic bronchitis (AECB): What is new?" CHEST (2005)
  • "Role of infection in acute exacerbations of chronic bronchitis (AECB)." CHEST (2005)
  • "A Sterile Airway Is A Happy Airway: Antibiotics. Symposium: Prevention of COPD exacerbation: are we there yet?" American Thoracic Society International Conference (2005)
  • "Airway Infection and COPD Progression. Symposium: New frontiers in the progression of COPD." American Thoracic Society International Conference (2005)
  • "Pathogenesis of and Immune Response to Bacterial Infection in COPD. Symposium: Airway infections: Pathogenesis and consequences." American Thoracic Society International Conference (2005)
  • "Role of Microorganisms in Disease Progression." American Thoracic Society International Conference, Postgraduate Course Session: COPD: State of the art for the clinician and Researcher (2005)
  • "New approaches to understanding AECOPD and current therapeutic trends." ECCMID (2005)
  • "Bacteriology of Acute Exacerbations. Panel Discussion: Update in Acute Exacerbations" CHEST (2004)
  • "Bacterial Pathogenesis of AECB – understanding the role of bacteria in AECB" European Respiratory Society Annual Congress (2004)
  • "Bacterial Infection in COPD: Phenomenon or Epiphenomenon" Copeland lecture, St Vincent’s Hospital (2004)
  • "Role of bacteria-colonization versus exacerbations. Plenary session on exacerbations." COPD 4 (2004)
  • "Bacteria - cause or innocent bystander" American Thoracic Society International Conference (2004)
  • "Immune response to bacterial pathogens in COPD" American Thoracic Society International Conference (2004)
  • "Bacterial pathogenesis of AECB." Third Forum on Respiratory Tract Infections (2004)
  • "The role of bacteria in COPD and AECOPD." CHEST International Conference (2003)
  • "Acute exacerbations of COPD: more than “chest colds”" American Thoracic Society International Conference, (2003)
  • "Microbes and exacerbations of COPD, old friends or new enemies?" American Thoracic Society International Conference, (2003)
  • "Bacteria in exacerbations of COPD" Exacerbations in COPD and Asthma: Mechanisms and Medicines Symposium. (2003)
  • "Bacterial Infection in COPD: Phenomenon or Epiphenomenon" New York State Thoracic Society Annual Scientific Assembly (2003)
  • "Bacteriology of acute exacerbations of chronic bronchitis." ATS International Conference (2002)
  • "Ventilator associated pneumonia" Second VA Critical Care Symposium (2002)
  • "Classification and differential diagnosis of acute exacerbations of chronic bronchitis" CHEST International Conference (2001)
  • "Role of viral respiratory infection in AECB, with a focus on Rhinovirus." CHEST International Conference (2001)
  • "Can we reduce the frequency of acute exacerbation of COPD?" Annual Advances in Pulmonary and Critical Care Medicine Symposium. (2001)
  • "New concepts in the pathogenesis of bacterial exacerbation of COPD" Annual Advances in Pulmonary and Critical Care Medicine Symposium. (2001)
  • "Bacterial persistence, eradication and dormancy" Forum on Respiratory Infections (2000)
  • "Ventilator-associated Pneumonia in the new millennium." City Wide Grand Rounds, State University of New York at Buffalo, Department of Medicine (2000)
  • "Bacterial infection in COPD" Aspen Lung Conference (1999)
  • "Acute Bronchitis. Acute exacerbations of chronic bronchitis and community acquired pneumonia - which antibiotic (if any) do we select?" ALA/ATS International Conference (1999)
  • "Airway inflammation in COPD: Role of bacterial infection." , Department of Medicine, State University of New York at Buffalo, City Wide Grand Rounds (1998)
  • "Role of infections in chronic bronchitis. National satellite video-conference: Challenges in Primary Care: Practical management of Chronic Bronchitis." Annual Scientific Assembly, Southern Medical Association, (1997)
  • "Bacteriologic considerations in patients with COPD. Panel Discussion: How to apply guidelines to antibiotic therapy in COPD patients." CHEST (1997)
  • "Acute bacterial infection in COPD patients: New Insights." Annual Advances in Pulmonary and Critical Care Medicine Symposium (1997)
  • "Parameters of clinical outcomes of AECB" Annual Advances in Pulmonary and Critical Care Medicine Symposium (1997)
  • "Bacterial infection in COPD: what’s new?" Southern California Pulmonary Research Conference. (1997)
See all (105 more)
Service Activities:
  • Canadian Institutes of Health Research; Ad Hoc Reviewer (2007)
  • European Commission Sixth Framework Programme; Ad Hoc Reviewer (2004)
  • Veterans Affairs Merit Review Program, VAMC.; Ad Hoc Reviewer (2003)
  • Member, Program Committee; Assembly on Clinical Problems, American Thoracic Society; Committee Member (2002–2011)
  • National Institute of Allergy & Infectious Diseases, National Institute of Health; National Institute of Allergy & Infectious Diseases, National Institute of Health; Ad Hoc Reviewer (2002)
  • Member, Program Committee; Assembly on Clinical Problems; Member (2002–present)
  • Member, Program Committee; Assembly on Microbiology, Tuberculosis & Pulmonary Infections. American Thoracic Society; Member (2002–present)
  • Advances in Therapy; Editorial Board Member
  • American Journal of Respiratory & Critical Care Medicine; Reviewer
  • American Journal of Respiratory Cell & Molecule Biology; Reviewer
  • American Journal of Respiratory Medicine; Reviewer
  • Antimicrobial Agents and Chemotherapy; Reviewer
  • BMC Pulmonary Medicine; Reviewer
  • Canadian Medical Association Journal; Reviewer
  • Chemotherapy; Reviewer
  • Chest; Reviewer
  • Clinical Drug Investigation; Reviewer
  • Clinical Investigation; Reviewer
  • Clinical Investigation; Editorial Board Member
  • COPD: Journal of Chronic Obstructive Pulmonary Disease; Reviewer
  • Critical Care; Reviewer
  • Current Drug Targets; Reviewer
  • Current Respiratory Medicine Reviews; Editorial Board Member
  • Current Respiratory Medicine Reviews; Editorial Board Member
  • Drugs and Aging; Reviewer
  • Editorial Board/Respiratory Research; Editorial Board Member
  • Epidemiology & Infection; Reviewer
  • European Respiratory Journal; Reviewer
  • Expert Opinion on Emerging Drugs; Reviewer
  • FEMS Immunology and Medical Microbiology; Reviewer
  • Human Genetics; Reviewer
  • Infection; Reviewer
  • Infection and Immunity; Reviewer
  • International Advisory Board/Thorax; Advisory Board
  • International Journal of Tuberculosis and Lung Disease; Reviewer
  • JAMA; Reviewer
  • Journal of Antimicrobial Chemotherapy; Reviewer
  • Journal of Cystic Fibrosis; Reviewer
  • Journal of General Internal Medicine; Reviewer
  • Journal of Infectious Diseases; Reviewer
  • Journal of Investigative Medicine; Reviewer
  • Journal of Medical Microbiology; Reviewer
  • Journal of Respiratory Diseases; Reviewer
  • Lancet; Reviewer
  • Lung India; Reviewer
  • New England Journal of Medicine; Reviewer
  • Nicotine and Tobacco Research; Reviewer
  • Pharmacoeconomics; Reviewer
  • PLosOne; Reviewer
  • PLosOne; Editorial Board Member
  • Proceedings of the American Thoracic Society; Reviewer
  • Pulmonary Pharmacology and Therapeutics; Reviewer
  • Respiration; Reviewer
  • Respiratory Medicine; Reviewer
  • Respiratory Research; Reviewer
  • Respiratory Research; Editorial Board Member
  • Respirology; Reviewer
  • Therapeutic Advances in Respiratory Disease; Reviewer
  • Thorax; Reviewer

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

VA WNY Healthcare System
3495 Bailey Avenue
Buffalo, NY 14215
Phone: (716) 862-7875
Fax: (716) 862-6526
Email: ssethi@buffalo.edu

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB Jacobs School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile